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USE OF POSITRON EMISSION TOMOGRAPHY  
FOR PROTON THERAPY VERIFICATION 
 
Jongmin Cho, B.E., M.S. 
Supervisory Professor: Geoffrey Ibbott, Ph.D. 
 
Positron emission tomography (PET), a tool commonly used for cancer staging and response 
monitoring, has recently been used for proton therapy verification. By imaging tissue 
activation following proton treatment, attempts have been made to verify proton dose and 
range. In this dissertation, two novel approaches were developed and tested for the purpose 
of help improve the proton dose and range estimation as well as verification. 
Although there are still some challenges, attempts for proton dose verification using PET 
has been made by comparing Monte Carlo dose and PET simulations with treatment planned 
dose and measured PET. In this approach, generic tissue composition information is used 
which can cause large uncertainties in Monte Carlo PET simulation. To improve these 
uncertainties, we developed a method in the first part of the research to obtain tissue 
elemental composition using PET after proton therapy. Proton activation of tissue creates 
progeny radioisotopes according to constituting tissue elements’ cross sections and proton 
energies. The time-activity-curves from activated tissues can be separated into constituting 
progeny radioisotopes using a least squares method and then to constituting elemental 
compositions using Monte Carlo simulated proton energy and cross-section information. We 
tested this approach using a phantom consisting of sections composed of different 
combinations of 12C and 16O irradiated using a mono-energetic and a SOBP proton beam. In 
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addition, two patient studies were also evaluated using the same technique immediately after 
proton treatments. The 12C and 16O compositions were estimated within 3.6% accuracy in 
the phantom studies and within 15.2% for patient studies. The obtained tissue elemental 
composition can be used to improve proton dose verification using PET. 
In the second part of this dissertation, we developed a new approach to verify proton range. 
Conventional proton range verification is performed by correlating the distal end of 
measured PET signals to the proton range. However, this approach is affected by minimal 
tissue activation near the end of the proton range, perfusion-driven activity washout, and 
short half-lives of progeny radioisotopes. This also requires an in-beam, in-room, or on-site 
PET scanner which can be financially and technically challenging for many proton centers. 
Our new approach overcomes all of these limitations by using proton activated markers. 
When implanted near the proton distal end, those markers are strongly activated while 
tissues are minimally activated. For this work we tested 18O enriched water, Cu and 68Zn 
enriched markers that were embedded in tissue-equivalent materials and imaged using an 
off-site PET scanner following proton activation. The marker materials provided 
significantly stronger PET signals near the distal end which can be used to verify proton 
range. In addition, optimal volumes of those markers were also investigated when imbedded 
in tissue-equivalent materials while using clinical treatment and imaging scenarios. Our 
results suggest that marker volumes ranging between 5 and 50 mm3 are required to provide 
adequate PET signals. The proposed approach can potentially replace conventional fiducial 
markers with the added benefit of proton range verification. 
Two proposed methods performed in this research can be used potentially improve both 
proton dose verification using PET and proton range verification using an off-site PET. 
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Chapter 1 
Introduction 
__________________________________________________________________________ 
 
 
 
Proton irradiation causes tissue activation that subsequently decays among others by 
positron emission which can be imaged using a PET scanner. Research in this field has 
focused on verifying the delivered dose and range of the proton beam by detecting the 
corresponding positron emission using an in-beam, in-room or on-site PET scanner 
primarily due to the short half-lives of endogenous activated tissues. However, accurate dose 
verification using PET imaging still has some challenges and one of which is a lack of 
knowledge about the constituent elemental tissue composition which generated the detected 
PET signal and which is essential for dose calculation. Furthermore, finding a relationship 
between proton range and PET signals is a challenge because most endogenous tissue 
elements have relatively high energy thresholds for proton nuclear activation, and therefore 
result in a low PET signal near the distal end of the proton beam where the proton energies 
are low. Additionally, the large uncertainties in biological washout models for the irradiated 
tissues also impede accurate proton dose and range verifications using PET imaging.  
The rationale of my PhD work is to improve proton dose and range verifications 
using PET imaging. To help the current attempts for proton dose verification possible, I 
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proposed a technique which determines the underlying elemental composition of activated 
tissues using PET imaging. Elemental tissue composition can be determined using PET 
imaging by decoupling the detected signal into its constituent decaying radioisotopes that 
represent a unique signature of the parent activated element. Elemental tissue composition is 
essential not only for dose and range calculation according to Bethe formula (stopping 
power calculation), but also for dose and range verification using PET. Currently, 
Hounsfield Unit (HU) dependent generic elemental composition information is used in CT 
based stopping power calculation also for dose verification using PET, even though tissues 
with the same HU can have vastly different elemental compositions, leading to inaccurate 
stopping powers as well as dose verification.  
Furthermore, to improve the current method of proton range verification, I proposed 
the development of implantable proton activated markers for range verification using the 
following stable isotopes: 18O, 63Cu and 68Zn.  All of them have high cross sections and low 
energy thresholds for proton activation. When activated with protons, they decay by positron 
emission with relatively long half-lives. The activated products therefore result in a high 
PET signal near the distal end of the proton beam range. The long half-lives obviate the need 
for expensive in-beam, in-room or on-site PET imaging. In addition, markers implanted at a 
fixed location in tissue do not suffer from biological washout and eliminate the need for 
accurate tissue element composition and cross section information. All of these attributes 
motivate the proposed marker to serve as a proton activated range verifier. 
 
1.1 Hypotheses 
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Since the rationale of my PhD research is to help improve both the proton dose and range 
verification, my hypothesis consists of two parts; one focusing on proton dose verification 
while the other on proton range verification. The following is the overarching hypothesis of 
my PhD dissertation. 
 
“PET imaging of proton activation can help improve proton therapy verification as well as 
proton range verification” 
The following is two specific hypotheses. 
1) PET imaging of proton activation can be used to determine the elemental tissue 
composition with an uncertainty of 10% (without accounting for biological washout). 
2) PET imaging of proton activated novel elements manufactured as patient implantable 
markers can be used to determine the proton range. 
 
1.2 Specific Aims 
 
To verify the hypotheses, three specific aims were constructed with Aim I focusing on the 
first hypothesis and Aims II and III focusing on the second hypothesis. The following are 
the three specific aims.  
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Aim I 
“Estimate the elemental composition of a phantom composed of 12C and 16O within a 10% 
uncertainty using 2 Gy mid-energy proton beams. This will be done using Monte Carlo 
simulation and PET imaging studies and the results will be compared to the true 
composition.” 
Aim II 
“Characterize the dose versus activation relationship with depth at the distal fall-off region 
for 18O, Cu and 68Zn using a mid-energy proton beam. This will be done using Monte Carlo 
simulation and PET imaging studies using tissue equivalent phantoms and materials, 18O 
enriched water, natural Cu foils and 68Zn enriched metal foils.” 
Aim III 
“Characterize the sensitivity of Cu and 68Zn markers embedded in two tissue-equivalent 
phantoms (lung and soft-tissue equivalent) by irradiating them at its maximum activation 
depth using a mid-energy proton beam. This will be done using various volumes (50 mm3, 
20 mm3, 10 mm3) of markers, irradiated by various dose (1, 2, 3, 5 Gy), and PET scanned 
with different acquisition times (20, 30, 40 min).” 
 
1.3 Dissertation Organization 
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The dissertation consists of the following: Chapter 1 presents the research with its rationale 
and significance. Chapter 2 introduces some background on proton therapy and proton 
therapy verification. Chapters 3, 4, and 5 present research from each Specific Aim. Chapter 
6 discusses possible future research in relation to each specific aim. Chapter 7 summarizes 
the research of each specific aim with concluding statements. 
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Chapter 2 
Background 
__________________________________________________________________________ 
 
 
 
2.1 Proton Therapy  
 
Proton therapy is becoming widely available worldwide due to the increased acceptance on 
its effectiveness. Currently, 42 proton therapy centers (14 in the US) are in operation 
worldwide, 25 centers (9 in the US) are under development and 11 more centers (1 in the 
US) are in planning stages. Since its first use at Berkeley Radiation Laboratory in 1954, 
more than 100,000 patients have been treated using protons so far for various types of 
cancer in sites such as the eye, brain, head-neck, lung, breast, prostate and many others. As 
first suggested by Robert Wilson in 1946, the advantage of proton therapy is that the 
maximum radiation dose (at the Bragg peak) is deposited just before the end of the proton 
path; beyond this point, the dose quickly falls to zero (Wilson 1946). An ideal treatment can 
be performed by placing the end of the proton path at the distal interface of a target with the 
normal structure.   
For the passive scattered technique which still is a main method of proton treatment, 
a mono-energetic proton beam that is accelerated to a desired energy is modified using 
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devices such as scatterers, a modulator and a compensator so that the maximum dose is 
uniformly deposited over a target while no dose is delivered to the distal normal or critical 
structure (Paganetti 2012a). Once a proton leaves the accelerator, it starts to lose energy 
according to the stopping power of the medium it goes through. The end of the proton path 
or the proton range occurs where the proton loses all of its energy and comes to stop. 
Stopping power which governs the energy loss of charged particles determines the pattern of 
energy (dose) deposition along the path and its range. Bethe-Bloch formula which calculates 
stopping power requires two medium specific inputs – electron density and elemental 
composition (Bichsel 1972, Schneider et al 1996). Once this information is given, stopping 
power can be calculated which in turn estimates the proton dose and range quite accurately 
(Schneider et al 1996, Yang et al 2010). Although the proton beam loses energy while going 
through beam modifying devices, its energy distribution is well defined at the location 
where the beam enters the patient. For this, various techniques such as Monte Carlo 
simulation or the percentage depth dose (PDD) measurement in a water (whose stopping 
power is well known) tank is used. Therefore, the only problem at hand for accurate dose 
and range estimation is the calculation of stopping power in patients. 
Currently patient specific stopping power is obtained by bilinear transformation of 
Computed Tomography (CT) measured HU (or relative attenuation coefficient) to relative 
stopping power. Calculation of patient specific stopping power using patient HU alone has 
been suggested to create uncertainties ≥ 2% (Paganetti 2012b) and these propagates to > 
3.5% proton range uncertainty when other confounding factors such as CT calibration 
differences and energy dependence are taken into consideration (Mustafa and Jackson 1983, 
Alpen et al 1985, Moyers et al 2010). While providing tissue elemental composition is 
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beneficial for reducing these uncertainties, Schneider et al 2000 attempted to correlate HU 
with tissue elemental composition. Although the correlations of H, N, P, and Ca with HU 
were found within a few percentage points, the correlations with C and O were uncertain to 
23%. This represents a major deficiency since C and O comprise the majority of human 
tissues and hence heads to inaccurate stopping power calculations. 
The uncertainties in the bilinear transformation of HU to stopping power and the 
resultant proton range uncertainty, both restrict proton treatment plans to beams that only 
cover the target without any distally located critical structure. This often prevents using the 
beam configurations with the shortest beam path (or minimum proximal normal tissue 
irradiation). For example, two lateral fields (LAT) are used for the prostate cancer although 
anterior-posterior (AP) and posterior-anterior (PA) fields provide benefits of less normal 
tissue irradiation and sharper penumbra. Also, patched fields (adjoining distal and lateral 
edges of two beams) can be used to cover the target without using the beam directed towards 
the distal critical structure (Lomax et al 2001). However, this can cause non-uniform target 
coverage with cold or hot spots at the field junctions. Besides that, often proton beam with 
larger margins (longer and wider than the optimal range and modulation, respectively) are 
prescribed to ensure the full coverage of the target. Although all those practices are less than 
ideal, they are considered as safe proton therapy practices due to the uncertainties in patient 
specific stopping power and proton range (Unkelbach et al 2009). 
Due to these uncertainties in converting CT obtained HU to patient specific stopping 
power, a direct measurement of proton stopping power using proton radiography or proton 
computed tomography (proton CT) has been suggested (Hanson et al 1982, Zygmanski et al 
2000). Proton radiography has the advantage of delivering significantly less dose to patients 
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(Moffett et al 1975; Schneider and Pedroni 1995; Schneider et al 2004) and providing 
superior contrast (Koehler 1968; Steward and Koehler 1973a, 1973b, Kramer et al 1977) 
compared to X-ray radiography. The greatest advantage of using proton radiography or 
proton CT for proton therapy is that they can directly measure both proton stopping power 
and proton residual range (Cookson 1974; Cormack and Koehler 1976; Schulte et al 2002; 
Penfold et al 2009). Despite its great potential, the clinical use of proton radiography or 
tomography for patient specific proton stopping power or range measurement seems not 
likely to happen in the near future. The main obstacle is the technological and financial 
challenges in building a proton gantry that delivers very high energy protons (that will pass 
through the entire body diameter) synchronized with gantry rotation.  
 
2.2 Proton Therapy Verifications 
 
Due to all the limitations and uncertainties discussed above, it is not yet possible to generate 
a proton therapy plan that will treat exactly the same as planned. Therefore, the focus of 
some research groups has shifted from reducing these uncertainties to verifying actual 
treatments. The rationale is that by verifying the accurateness of proton therapy before, 
during or after the treatment, the original treatment plan can be modified to improve the 
current or future treatment. In X-ray therapy, confirming MV radiographs using actual 
treatment fields and portal dosimetry using exit dose are good examples of treatment 
verification occurring before and during treatments. However, this type of treatment 
verification is not possible for proton therapy due to the nature of not having exit dose.  
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Although exit dosimetry is possible by using proton radiography to monitor the change of 
radiographic path length along the treatment beam path, it is not verification of the actual 
treatment beam but instead of a high energy proton beam passing through the entire body 
diameter. This approach implicates some uncertainties for including tissue regions that 
wouldn’t be involved in actual treatments. 
In this following, we will discuss some of currently proposed or used proton therapy 
and range verifications methods of actual treatment beams. Min et al 2006 suggested the use 
of prompt gamma ray emission following proton treatment for proton therapy verification. 
When high energy protons interact with tissues, tissue nuclei are excited and decay promptly 
to the ground state while emitting gamma rays of several MeV. Due to the prompt nature of 
gamma ray emission and its proximity to the Bragg peak location, it can be used as a good 
real-time proton range verification tool. Besides, the energy of each prompt gamma ray is 
nuclei dependent, therefore it can be used to determine tissue elemental composition (Polf et 
al 2009). Despite its great potential, the construction of efficient detectors is still 
technologically and financially challenging and no immediate use is expected in the near 
future for patient treatment verification.   
Also, magnetic resonance imaging (MRI) was suggested for proton therapy 
verification by imaging changes in tissue property caused by ionizing radiation. Ionizing 
radiation causes tissues to go through various changes including reduction in cellularity as 
well as an increase in fat and marrow edema – these changes are thought to be picked up by 
MRI (Stevens et al 1990, Blomlie et al 1995). Gensheimer et al 2010 investigated and 
observed changes in MR signals in the irradiated spines from 10 proton spine patients. The 
distinctive difference in MR signals between the proximal and distal region of the expected 
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proton dose fall-off can be used for proton range verification. However, according to 
Stevens et al 1990, Yankelevitz et al 1991 and Blomlie et al 1995, these tissue property 
changes start after few to 8 days and completes after 3 months since the beginning of the 
radiation treatment course. Therefore, proton therapy verification using MRI seems more 
adequate for retrospective proton therapy or range verification.  
Lu (2008a) and Gottschalk et al (2011) suggested the use of a small ion chamber or 
semiconductor diode for time-resolved proton range verification. A metal oxide 
semiconductor field effect transistor-based implantable dosimeter with wireless 
communications (Sicel Technologies Inc., Morrisville, NC) is commercially available and 
used at several clinical sites for in vivo dosimetry after x-ray therapy. This dosimeter has a 
cylindrical shape with dimensions of 2.1 mm in diameter and 2 cm in length (volume of 70 
mm3) and also can function as a radiographic fiducial maker (Scarantino et al., 2005). 
Several investigators have suggested and tested proton range verification using those 
implanted dosimeters (Lu et al 2010). However, one cannot estimate proton range by 
implanting those dosimeters at the SOBP region because the dose is uniform there, and it is 
difficult to implant such dosimeters at the dose fall-off region, although doing so would 
provide excellent proton range verification. To overcome these problems, Lu (2008b) 
suggested that the proton path length be verified by measuring a ratio of two doses, each of 
which is obtained by dividing the currently available passive flat SOBP profile into two 
oppositely sloped depth dose profiles. Despite its great potential, it has a disadvantage of 
being invasive, providing only point verification versus volumetric verification and lastly 
requiring modification of the current treatment practices (dividing a SOBP beam into two 
sloped fields). 
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Furthermore, positron emission tomography (PET) has been suggested for in vivo 
proton dose and range verification after proton tissue activation (Paans and Schippers 1993, 
Oelfke et al 1996, Litzenberg et al 1999, Nishio et al 2005, Crespo et al 2006, Parodi et al 
2007a, 2007b, Knopf et al 2008). During proton treatment, irradiated tissue is activated and 
decays among other schemes by positron emission, which subsequently results in 
annihilation photons that can be imaged using a PET scanner. Due to the short half-lived 
nature of activated tissues, scanners with minimum post-irradiation delay (in-beam, in-room 
or on-site PET scanners) are preferred. Among various verification methods, verification 
using PET is technologically most mature and promising in both proton and heavy ion (such 
as carbon) therapies (Fiedler et al 2010). Although it is still limited to two carbon ion 
therapy centers, in-beam PETs are being used for routine clinical practices for therapy and 
range verification (Urakabe et al 2001, Enghardt et al 2004, Parodi et al 2007b, Nishio et al 
2008). The proton dose and range verification using PET can be realized by correlating 
tissue PET signals with dose deposition and proton range. However, there are several 
challenges in correlating entirely two different physics – electromagnetism for proton dose 
and range and nuclear physics for PET signals. Remmele et al 2011 performed a PET-based 
dose construction using a deconvolution approach but it seems not applicable to general 
heterogeneous media. In the subsequent chapters, I will discuss those challenges and suggest 
approaches to overcome those, followed by the research performed.  
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Chapter 3 
Determination of Elemental Tissue Composition following Proton 
Treatment using Positron Emission Tomography 
__________________________________________________________________________ 
With permission of IOP (Institute of Physics) Publishing, this chapter is based on the 
following article: Cho J, Ibbott G, Gillin M, Gonzalez-Lepera C, Min C H, Zhu X, El Fakhri 
G, Paganetti H and Mawlawi O 2013 Determination of elemental tissue composition 
following proton treatment using positron emission tomography Phys. Med. Biol. 58 3815-
35.  
 
3.1 Introduction  
 
In the earlier chapter, we discussed the importance of providing patient specific tissue 
elemental composition for accurate proton stopping power calculation. An example will be 
CT stoichiometric calibration (using known tissue elemental composition) being more 
accurate than tissue substitute calibration (using tissue substitute materials that have 
different elemental compositions than real tissues) in HU to stopping power correlation 
(Schneider et al 1996). Jiang et al 2007 also showed that inaccuracies in tissue elemental 
composition for stopping power calculation can produce large errors in proton range 
calculation (Jiang et al 2007). Even small uncertainties in stopping power can result in a 
significant range uncertainty because the range is the accumulated outcome of proton 
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stopping power along the proton path (Jiang and Paganetti 2004, Matsufuji et al 1998, 
Mustafa and Jackson 1983). Moyers et al 2010 also found that the calculated CT number 
(from calculated relative attenuation coefficient (Mustafa and Jackson 1983)) of certain 
materials differ as much as 49% from their measured CT numbers when their exact 
elemental compositions are unknown. This uncertainty was reduced to ± 4 % when the 
elemental composition was known (Moyers et al 2010). The above investigations suggest 
that uncertainties in elemental compositions increase the uncertainty in stopping power 
calculation which leads to inaccurate proton dose and range calculation. 
However, their impact on dose and proton range calculations is not significant within 
the normal variation of elemental composition in soft-tissue. It is because the most variation 
occurs in carbon, nitrogen and oxygen fractions which have quite similar atomic numbers.  
Therefore, the additional uncertainty in proton range due to the elemental composition 
uncertainty alone is < 1% of the total proton range (Matsufuji et al 1998, Schaffner and 
Pedroni 1998, Paganetti 2012b). Yang et al 2010 also reported on low uncertainty (< 1%) in 
stopping power calculation for up to 5% variation of O and C composition using both 
stoichiometric and dual energy CT methods although variations in H and Ca gave rise to 
larger uncertainties (up to 5%). 
However, Monte Carlo study performed using different CT conversion algorithms 
shows that Monte Carlo simulated PET is more sensitive than Monte Carlo simulated dose 
to differences in CT numbers assignment to different materials (or elemental composition) 
(España and Paganetti, 2010). Several other investigations show that accurate knowledge of 
the tissue’s elemental composition is significantly important for correlating activation with 
dose (Parodi et al 2007b, Knopf et al 2009, Knopf et al 2011, España et al 2011). While the 
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dose in tissue is governed by the stopping power, tissue activation is governed by nuclei 
specific proton interaction cross sections which are two entirely different processes. Nuclei 
in tissue create different progeny radioisotopes as functions of proton energy interacting 
with them. In other words, two adjacent regions with different tissue elemental compositions 
can have different time-dependent PET signal intensities, even though they were irradiated 
by the same proton spectrum and dose (Cho et al 2013a). A good example can be that 
adipose tissues which are rich in carbon tend to create more 11C (T½ = 20 min) than muscles 
which are rich in oxygen, therefore, adipose tissues show higher PET signals than muscle in 
the delayed long PET scan while muscles show higher PET signals from 15O (T½ = 2 min) 
in the minimum delayed short PET scan. Therefore, it is not possible to accurately correlate 
the tissue activation with the delivered dose without correct elemental composition 
information about the irradiated tissue.  
In this study, we investigated whether PET imaging can be used to determine tissue 
elemental composition in a phantom as well as in patients who have undergone proton 
therapy. If successful, we envision that patients will be able to undergo PET scanning with 
an in-room PET scanner after the first proton treatment. The obtained tissue elemental 
composition information can be used to verify and potentially correct the original proton 
treatment plan, which had been based on a HU to stopping power conversion curve. 
Although there are still some other challenges, we also envision that providing tissue 
elemental composition will improve dose verification using PET. By normalizing tissue PET 
signals with the correct tissue elemental composition information, more accurate correlation 
between the PET signal and the delivered dose becomes possible. To our knowledge, this 
work is the first to use PET to analyze patients’ tissue elemental composition. 
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3.2 Materials and Methods  
3.2.1 Phantom Activation and PET Imaging 
A phantom consisting of three 12-cm long sections that were composed of high-
density polyethylene (HDPE), water gel, and tissue gel, respectively, was proton 
irradiated at the Francis H. Burr Proton Therapy Center (Massachusetts General 
Hospital, Boston, MA). The phantom and corresponding elemental composition 
fractions are shown in figure 3.1 and table 3.1, respectively. Because HDPE, water 
gel, and tissue gel consist mostly of 12C, 16O, and a mixture of 12C and 16O, 
respectively, they will be hereafter referred to as 12C phantom, 16O phantom, and 
12C+16O phantom, respectively. The composite phantom was activated using two 
116-MeV proton beams—a pristine Bragg peak (1.6 Gy) and a 6-cm spread-out 
Bragg peak (SOBP) beam (2 Gy). The time interval between the 2 beams was 2 
hours. A square field of 7 × 7 cm2 was used to irradiate the phantom, as shown in 
figure 3.1. Within 1 minute after each proton activation, the phantoms were moved 
to a mobile PET scanner (NeuroPET, Photo Diagnostic Systems, Boxboro, MA) that 
was placed immediately adjacent to the treatment couch and imaged for 30 minutes 
in list mode. PET data were then sorted into 30 1-minute data sets and reconstructed 
with no decay correction. The reconstructed PET voxels were 2 × 2 × 1.925 mm3. 
Volumes of interest (VOIs) of 2 × 2 × 1 cm3 were then drawn on each phantom 
section at 1-cm water equivalent thickness intervals and the PET signal from every 
VOI was averaged. The details of the PET data acquisition and of the reconstruction 
are discussed in España et al 2011. 
 
 
 
 
Figure 3.1 A 12-cm long phantom was irradiated with near monoenergetic and 6-cm SOBP 
proton beams, followed by PET scans. It consisted of three sections composed of high-
density polyethylene (HDPE), water gel, and tissue gel, respectively. 
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Table 3.1 Elemental compositions of three phantoms.  
Phantom 
Elemental composition (% by weight) 
16O 12C 1H 14N Density (g/cm3) 
HDPE (12C phantom) 0.0 85.7 14.3 0.0 0.95 
Water gel (16O phantom) 87.6 1.04 11.03 0.32 1.01 
Tissue gel (12C+16O phantom) 73.8 14.9 9.6 1.46 1.13 
 Elemental composition (% by atomic fraction) 
Tissue gel (12C+16O phantom) 78.8 21.2 Fractions of 1H and 14N not counted 
- Natural abundances of the above isotopes are 98.89%-99.99%. 
- 
1H is not proton activated and therefore does not contribute to positron emission. 
 
The irradiated phantoms create multiple positron-emitting radioisotopes. For 
example, 16O atoms create 11C, 13N, and 15O isotopes after proton irradiation. When a 
sample with T atoms in voxel r and density ρT(r) is irradiated using a proton beam 
with a fluence of ΦE(r,t), each resulting isotope I is created according to its isotope 
production cross section, σTI(E(r)), while simultaneously decaying according to its 
specific half-life. After irradiation, the activity from the remaining radioisotopes at 
time t (t = 0 when irradiation was complete) in voxel r is 
 
aI(r,t) = ∑T ρT(r) ΦE(r,t) σTI(E(r)) (1–e-λI tR) e- λI t    (3.1) 
 
where λI and tR are the isotope decay constant and irradiation (beam-on) time, 
respectively. This formula considers the number of created and decayed atoms of 
radioisotope I during tR.  
 
3.2.2 Method of Decoupling Decay Curves 
 
After proton irradiation, 12C, 14N, and 16O atoms in the composite phantom are 
activated to several radioisotopes that decay by positron emission. Because HDPE, 
water gel, and tissue gel consist mostly of 12C and 16O (see table 3.1), other elements 
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such as 14N in the 12C+16O phantom and 12C and 14N in the 16O phantom have low 
fractions (< 2%) and are ignored.  
 
Activation of the 12C phantom creates 10C and 11C; these simultaneously 
decay with half-lives of 19.29 seconds and 20.33 minutes, respectively (eq. 3.2). The 
relative fractions of 10C and 11C radioisotopes is governed by factors such as proton 
nuclear cross section, proton beam energy and fluence, and proton beam time, as 
shown in eq. 3.1. In the same way, the activated 16O phantom creates 11C, 13N, and 
15O, which simultaneously decay with half-lives of 20.33 minutes, 9.96 minutes, and 
122.24 seconds, respectively (eq. 3.3). Proton interaction channels and nuclear 
interaction cross sections for 12C and 16O are shown in table 3.2 and figure 3.2. 
 
Table 3.2 Proton interaction channels and half-lives of β+ emitting progeny radioisotopes of 
12C and 16O.  
 
Element Proton-element interaction channel (half-life of progeny radioisotope) 
12C 12C(p,pn)11C (20.23 min), 12C(p,p2n)10C (19.29 sec) 
16O 16O(p,αpn)11C (20.23 min), 16O(p,α)13N (9.96 min), 16O(p,pn)15O (122.24 
sec) 
- 
16O(p,p2n)14O (70.61 sec) and 16O(p,3p4n)10C were ignored because of their small 
contributions (small interaction cross sections and short half-lives). 
 
Activated 12C = α 11C + β 10C   (3.2) 
Activated 16O = α' 11C + β' 13N + γ' 15O  (3.3) 
 
where α, β, α', β', γ' are the relative fractions of created radioisotopes. α and β are 
determined as best-fit parameters when the summation of 2 simple exponential decay 
curves, with half-lives of 20.33 minutes and 19.29 seconds, is fitted to the PET time 
activity curve from activated 12C, using a least-square technique (figure 3.3(a)). The 
details of how to separate multiple PET tracers from a single decay curve using the 
least-squares method can be found in Huang et al 1982.  
 
In the same way, α', β', and γ' can be obtained from the activated 16O phantom 
(figure 3.3(b)). α, β, α', β', γ' are depth dependent because proton energy and fluence 
change with depth and proton nuclear cross sections change with proton energy. 
Therefore, the above procedure was repeated at 1-cm depth intervals along the length 
of the phantom to determine the corresponding α, β, α', β', and γ'.  
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Figure 3.2 Proton nuclear interaction cross sections of 12C and 16O (Nishio et al 2008).  
 
Activation of the 12C+16O phantom is more complex because it consists of 2 
elements. However, the same technique can still be used to determine the elemental 
composition and fraction of each element. Activating the 12C+16O phantom creates 
the radioisotopes 10C, 11C, 13N, and 15O, with each radioisotope fraction dependent 
on proton energy, fluence, and amount of 12C and 16O in the 12C+16O phantom:  
 
Activated 12C+16O = α'' 10C + β'' 11C + γ'' 13N + δ'' 15O  (3.4) 
 
The raw decay curve from the activated 12C+16O phantom can be separated into 4 
exponentials—α'', β'', γ'', and δ''—using the method of least-squares, whose 
summation (fit) agrees with the raw decay curve (figure 3.4(a)). This separation 
alone, however, cannot determine the fraction of 12C and 16O in the 12C+16O phantom 
because β'' is a compound factor that is contributed to by 12C and 16O activation (see 
eqs. 3.2 and 3.3). One approach to determine the 12C and 16O fraction in the 12C+16O 
phantom is to equate its activation with the sum of 12C and 16O activations. Such a 
method of determining the fractions of induced isotopes in a mixed target from the 
activity in pure targets was first described by Priegnitz et al. 2008 and Priegnitz et al. 
2012. A similar approach has been also developed by Miyatake et al. 2009 and 
Miyatake et al. 2011. 
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(a) 
 
(b) 
 
Figure 3.3 (a) Activated 12C was decoupled into 2 simple exponential decay curves that 
corresponded to progeny radioisotopes, 11C and 10C. The sum of those 2 exponential decay 
curves was in agreement with the original PET decay curve. (b) Activated 16O was 
decoupled into 2 simple exponential decay curves that corresponded to progeny 
radioisotopes: 11C, 13N, and 15O. The sum of those 3 exponential decay curves was in 
agreement with the original PET decay curve. Goodness of fit (R2) is shown. 
R
2
 = 0.999 (Raw PET vs Sum of decoupled radioisotopes) 
R
2
 = 0.994 (Raw PET vs Sum of decoupled radioisotopes) 
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Activated 12C+16O = a activated 12C + b activated 16O 
α'' 
10C + β'' 11C + γ'' 13N + δ'' 15O = a (α 11C + β 10C) + b (α' 11C + β' 13N + γ' 15O)     (3.5)  
Activated 12C+16O = a' (11C + α''' 10C) + b' (11C + β''' 13N + γ''' 15O)      (3.6) 
 
where a and b are the relative contributions (or fractions) of 12C and 16O, respectively 
in the activated 12C+16O (figure 3.4(b)). Here, the factor β'' from eq. 3.4 has been 
separated into 2 components, a' and b' (or aα and bα'), which are the 11C 
contributions from the activated 12C and 16O, respectively. Here α''' = β/α, β''' = β'/α', 
and γ''' = γ'/α'. Because α, β, α', β', and γ' (and also α''', β''', and γ''') have already 
been determined at each depth, a' and b' for each depth can be calculated by 
minimizing the root mean square error between the raw decay curve of the 12C+16O 
phantom and the sum of the best fits of the 2 decay curves of 12C and 16O (eq. 3.7): 
 
Least squares to be minimized to obtain a' and b' = 
(Activated 12C+16O - a' (11C + α''' 10C) - b' (11C + β''' 13N + γ''' 15O))2  (3.7) 
 
Please note that it is not necessary to determine α'', β'', γ'', and δ'' since a' and b' are 
determined by fitting activated 12C and activated 16O curves to the raw decay curve 
of the 12C+16O phantom (the activated 12C+16O) using the least squares method. 
The fractions of 12C and 16O can then be calculated by 
 
Fraction of 12C = a' / α = a  (3.8) 
Fraction of 16O = b' / α' = b  (3.9) 
 
The 11C activity from the 12C and 16O phantoms (α and α') was determined by 
normalizing the PET signals from each phantom with the unit density of each atom 
(12C or 16O). The above procedure is summarized in figure 3.4(c), which shows how 
the raw PET decay curve from the activated 12C+16O phantom was decoupled into 
12C and 16O decay curves; each curve was then decoupled into simple exponential 
curves that corresponded to its progeny radioisotopes. The sum of all simple 
exponential curves was in agreement with the raw PET decay curve.  
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(a) 
 
 
R
2
 = 0.998 (Raw PET vs Sum of decoupled radioisotopes) 
R
2
 = 0.998 (Raw PET vs Sum of decoupled radioisotopes) 
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(b) 
 
 
(c) 
 
Figure 3.4 (a) Activated 12C+16O were decoupled into 4 simple exponential decay curves 
that corresponded to the progeny radioisotopes 10C, 11C, 13N, and 15O. The sum was in close 
agreement with the raw PET decay curve. (b) The curve from the activated 12C+16O was 
decoupled into the 12C and 16O decay curves, and their sum was in agreement with the raw 
PET decay curve. (c) The original decay curve of activated 12C+16O was decoupled into 12C 
and 16O decay curves; each of these was decoupled into their progeny simple exponential 
decay curves. Here, the magnitude of 12C and 16O (a, b in eq. 3.5) was proportional to the 
fraction of 12C and 16O in the 12C+16O phantom. Goodness of fit (R2) is shown. 
 
 
To calculate the standard error, each fitting parameter (α, β, α', β', γ', a', and b') was 
calculated with not only for the best fit but also for the maximum and minimum 
possible values within a 95% confidence interval. This fitting parameter uncertainty 
in each step (12C fitting, 16O fitting and 12C + 16O fitting) was propagated to obtain 
the standard error of elemental composition estimation within the 95% confidence 
interval.  Additionally, R2 was calculated in each fitting to test the goodness of fit. 
Since short-lived isotopes such as 10C decay quickly during each PET image frame 
acquisition time (1 min), image-frame decay correction was applied to compensate 
for that. To evaluate the accuracy of this technique, we compared the 12C and 16O 
fractions with the true 12C and 16O fractions of the 12C+16O phantom over the depths 
of 0 to 10 cm.  
R
2
 = 0.998 (Raw PET vs Sum of decoupled radioisotopes) 
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3.2.3 Monte Carlo Simulation 
 
The above analysis requires activation (PET) decay curves from the 12C-only and 
16O-only phantoms to calculate the elemental composition from the activated 
12C+16O phantom. In a clinical setting, this approach cannot be easily implemented 
because it is not possible to irradiate 12C-only and 16O-only tissue or phantom during 
treatment. However, we investigated whether the 12C-only and 16O-only phantom 
activation could be replaced with Monte Carlo simulation, hence restrict the 
activation and PET decay curve analysis to the 12C+16O phantom or patients.   
 
A Monte Carlo simulation was performed as a step of determining the 12C 
and 16O fraction in the 12C+16O phantom. First, the near monoenergetic and SOBP 
proton beams that had been used in the phantom activation study were simulated 
using GAMOS (Geant4-based Architecture for Medicine-Oriented Simulations) 
(Arce et al. 2008). The depth-dose profiles of the simulated proton beams were in 
agreement within 2% and 2 mm of the actual proton beams used in this study. The 
Monte Carlo simulated proton energy fluence at each phantom voxel was then 
integrated with the proton nuclear interaction cross section data of Nishio et al 2008 
to simulate radioisotope creation from proton-12C and proton-16O interactions. For 
example, the integration of the proton energy fluence with the cross sections, 
12C(p,pn)11C and 16O(p,αpn)11C gave rise to α and α', respectively. The MCNPX 
technique used by Seravalli et al 2012 was followed for this Monte Carlo simulation. 
All cross sections used for Monte Carlo simulations were obtained from the semi-
empirical equation developed by Nishio et al 2005, 2008, which is in agreement with 
the experimental data (Iljinov et al 1994) available at the EXFOR library from 
Brookhaven National Laboratory National Nuclear Data Center 
(http://www.nndc.bnl.gov/exfor/exfor00.htm). 
 
α and β (the relative fractions of 11C and 10C in the activated 12C phantom) 
and α', β', γ' (of the 16O phantom) were calculated at a 1-cm depth interval using the 
same-sized PET VOI as those used in the PET phantom study. α, β, α', β', and γ', 
calculated from the Monte Carlo simulation, were then used to decouple the PET 
signal obtained from the activated 12C+16O phantom. The same procedure used for 
eqs. 3.4-3.7 was used to calculate the elemental composition (fraction) of 12C and 
16O in the 12C+16O phantom.  
 
Once a' and b' had been determined, the elemental composition (fraction) of 
12C and 16O in the 12C+16O phantom was calculated as follows:  
 
Fraction of 12C = a' / ∫∫ΦE0(r,t) σ12C11C(E(r)) dr dE  (3.10)  
Fraction of 16O = b' / ∫∫ΦE0(r,t) σ16O11C(E(r)) dr dE  (3.11) 
 
Here, α and α' in eqs. 3.8 and 3.9 were replaced with the nuclear cross section, 
integrated over the proton energy fluence and track length. Please note that α and α' 
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are also functions of beam irradiation time, delay, and PET acquisition time and were 
calculated while taking these factors into consideration. After the Monte Carlo 
simulation, the obtained fractions of 12C and 16O were compared with the true 12C 
and 16O fractions of the 12C+16O phantom over depths of 0 to 10 cm. 
 
3.2.4 Clinical Study using Monte Carlo Simulations 
 
In addition to phantom imaging, we performed 2 patient studies to validate the 
proposed technique and determine the 12C and 16O tissue composition at specific 
beam locations. Both patients were enrolled in the study under a MGH Institutional 
Review Board (IRB) approved protocol. Monte Carlo simulations were used to 
determine the α, β, α', β', and γ' that were necessary to calculate the fractions of 12C 
and 16O in soft tissues (see details below). 
 
Delivered doses of 2 Gy from modulated proton beams with a range of 12.5 
cm and 11.7 cm were used to treat adenoid cystic carcinomas of the nasopharynx 
(patient 1) and lacrimal gland (patient 2), respectively; these patients underwent PET 
scans using a mobile PET scanner after an approximately 3-minute delay. PET data 
on patient 1 were acquired for 45 minutes in list mode and rebinned into 45 × 1-
minute frames. PET data on patient 2 were acquired for 30 minutes and rebinned into 
20 × 1 minute frames, followed by 5 × 2-minute frames. Additional information 
about the patient set-up and PET scans can be found in Zhu et al 2011. 
 
Patient treatment beams were Monte Carlo simulated using the code 
developed by Paganetti et al (2008), which is based on GEANT4. GAMOS (Arce et 
al. 2008) was used to calculate patient dose and activation. First, patient CT DICOM 
files were converted into specific density and elemental compositions using the 
method described by Paganetti et al 2008, which is based on that by Schneider et al 
2000. GEANT4-simulated patient treatment beams were irradiated on patient CT 
images to calculate a proton energy spectrum at each CT voxel (0.781 × 0.781 × 2.5 
mm for patient 1 and 0.547 × 0.547 × 2.5 mm for patient 2). By integrating the 
proton energy spectrum with the cross section data used above, we calculated α, 
β, α', β', and γ' (relative creation of each progeny radioisotope) for each PET voxel. 
Using this Monte Carlo-simulated relative creation of each radioisotope, we analyzed 
patient PET decay data from each voxel to calculate the relative fractions of 12C and 
16O.  
 
A 3-component biological diffusion model developed by Mizuno et al 2003, 
Tomitani et al 2003, and Parodi et al 2007b, 2008 was also used to account for the 
biological diffusion on top of the physical decay of PET signals from each voxel in 
patient studies. Using this biological diffusion model, we modified eq. 3.1 to 
represent the activity from the remaining radioisotopes I from the activated patient’s 
atom T at time t after proton irradiation: 
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aI
E(r,t) = ∑k=f,m,s Mk(r) ∑T ρT (r) ΦE(r,t) σTI(E(r)) (1–e-( λI + λbio,k(r)) tR) e- (λI + λbio,k(r)) t (3.12) 
 
where Mk (k = f(fast), m(medium), s(slow)) is the biological decay fraction in each 
voxel (r) and λbio,k (k = f(fast), m(medium), s(slow)) is the biological decay constant 
for the same voxel. The same biological decay parameters were multiplied in eq. 3.1 
to account for the biologic washout of PET signals on top of physical decay. Eqs. 3.2 
– 3.11 were then used to calculate the relative fraction of 12C and 16O in each PET 
voxel over the proton-irradiated tissue regions.  
 
To reduce fluctuation of the resultant activity in each voxel (2 × 2 × 1.925 
mm3), we smoothed them by averaging 3 × 3 × 3 neighboring PET voxels making 
the volume of each voxel equal to 6 × 6 × 5.775 mm3 before calculating α, β, α', β', 
and γ' and determining the relative fractions of 12C and 16O. To further reduce noise 
uncertainties, we discarded the voxels whose activity concentration was less than 8% 
of the maximum value in the first timeframe for patient 1 data and 20% of the 
maximum value for patient 2 data. These thresholds were chosen to help generate a 
continuous elemental tissue composition map as compared to multiple discontinuous 
islets. The calculated 12C and 16O fractions were then arranged as 2D maps and 
superimposed on patients’ axial CT images.  
 
Throughout this research, regression analysis was performed and R2 
(goodness of fit) was calculated between raw PET time activity curve at each PET 
volume / voxel. 2D map of R2 corresponding to each PET voxel were then 
superimposed on the CT images. To evaluate the accuracy of the relative fraction of 
12C and 16O in each PET voxel of the proton irradiated tissue regions, four 2-cm2 
ROIs were drawn on a single plane for patient 1 (adipose 1, adipose 2, brain 1, and 
brain 2) and patient 2 (vitreous humor, face mask / adipose tissue, and brain) , 
respectively. The relative fractions of 12C and 16O in these ROIs were then measured 
and compared with the published elemental composition data from ICRU 46 (ICRU 
Report 46).  
 
 Finally, we compared our 2D 16O and 12C elemental composition maps with 
the raw PET proton activation images to evaluate whether the latter can be a 
substitute for our elemental tissue composition maps. A short PET scan (0-5 minutes) 
raw image and delayed long PET scan raw image (15-45 minutes for patient 1 and 
15-30 minutes for patient 2) were first generated and then superimposed on the axial 
CT slices of patients 1 and 2. A short PET scan can be considered as a pseudo-image 
of an 16O-rich region because of the fast decay of 15O. A delayed long PET scan on 
the other hand can be considered a pseudo-image of a 12C-rich region because of the 
slow decay of 11C. The comparison of these image pairs was done using visual 
assessment. The contribution from fast decaying 10C was ignored due to 3 min delay 
from the end of activation to the beginning of PET scan. (Excerpted from Cho et al 
2013a) 
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3.3 Results 
Figure 3.5 shows the depth activity profiles for three phantoms irradiated by pristine 
peak and SOBP beams. Each point on the graph (figure 3.5(a) and (b)) corresponds 
to the cumulated activity of the activated phantom over a period of 30 minutes. 
 
Figure 3.3(a) shows the time-activity (decay) curve of the activated 12C 
phantom from a 4-cm3 volume (2 × 2 × 1 cm PET volume) located between the 
water-equivalent depths of 4 and 5 cm. The time-activity curve was decoupled into 2 
simple decay curves each corresponded to a progeny radioisotope (α and β obtained 
in eq. 3.2). Figure 3.3(b) shows the time-activity curve for the activated 16O phantom 
and the decoupled exponential curves from 3 progeny radioisotopes (α', 
β', and γ' obtained in eq. 3.3). Figure 3.4(a)–(c) shows the time-activity curve of the 
activated 12C+16O phantom from the volume at the same depth (4–5 cm) and its 
decomposition process. First, the raw PET decay curve was separated into 4 simple 
exponential curves using the least-squares method (figure 3.4(a); α'', β'', γ'', and δ'', 
obtained in eq. 3.9). This curve was decoupled into 2 decay curves—a 12C decay 
curve and 16O decay curve—by minimizing the root mean square error between the 
raw decay curve of the 12C+16O phantom and the sum of the best fits of the 2 decay 
curves of 12C and 16O (figure 3.4(b); eqs. 3.5–3.7). In this procedure, the optimal a 
and b (fractions of 12C and 16O) are obtained. The summary of the entire procedure is 
shown in figure 3.4(c). Please note that in the actual calculation, α'', β'', γ'', and δ'' are 
not computed since a and b are obtained by decoupling the raw PET decay curve into 
2 decay curves—a 12C decay curve and 16O decay curve, however, it is shown here 
for illustration. Excellent goodness of fit (R2 > 0.994) is shown between the raw PET 
decay and the sum of all decoupled radioisotope decays (fit) in both figures 3.3 and 
3.4.  
The procedure described above was repeated for the entire length of the 
phantom in 1 cm increments, and 12C and 16O (atomic) fractions were calculated 
according to eqs. 3.8 and 3.9 (eqs. 3.10 and 3.11 for the Monte Carlo method). 
Figure 3.6(a) and (b) shows actual versus estimated percentages of 12C and 16O in the 
12C+16O phantom for monoenergetic and SOBP proton beams, respectively. Error 
bars represent standard error within 95% confidence interval. The proposed 
elemental decomposition method estimated the fraction of 12C and 16O, with good 
accuracy, over a depth of 0–8 cm (figure 3.6). The accuracy at 8–10 cm, however, 
was lower. This lower accuracy can be attributed to: a) the small number of positrons 
generated at this depth, b) the rapid changes of α, β, α', β', and γ' near the distal 
penumbra of the proton beams and c) the differences in water equivalent thickness 
scaling between different phantoms. The peak of the nuclear interaction cross section 
occurs at around 40-50 MeV, below this energy, the activation of 12C and 16O 
decreases rapidly and α, β, α', β', and γ' also changes rapidly due to the cross section 
changes (figure 3.2). Proton energies at depths of 8–10 cm are mostly at the lower 
energy spectrum; therefore, the smaller number of positrons generated results in 
increased statistical uncertainty. When summed with other uncertainties mentioned 
above, these lead to a larger discrepancy between the measured and true fractions. 
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(a) 
 
(b) 
 
Figure 3.5 (a) Depth activation curves of 3 phantoms irradiated by a monoenergetic proton 
beam. (b) Depth activation curves of 3 phantoms irradiated with an SOBP beam.  
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(a) 
 
 (b) 
 
Figure 3.6 PET measurement method. (a) Estimated 12C and 16O (atomic) fractions at each 
phantom depth for a near monoenergetic beam. Actual percentages are shown as straight 
lines (refer to table 3.1). (b) Estimated 12C and 16O (atomic) fractions at each phantom depth 
for a SOBP beam. Actual (atomic) percentages are shown as straight lines. Error bars 
represent standard error at 95% confidence interval. 
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Figures 3.7(a) and (b) show the actual versus estimated fractions of 12C and 
16O, obtained using the Monte Carlo simulation. Standard error for Monte Carlo 
method was smaller than that of PET measurement method since the latter method 
involved 3 steps of fitting which propagated to a larger error while the former 
method required only one fitting (12C+16O). The Monte Carlo simulation estimated 
the fraction of 12C and 16O with similar differences to the actual value compared with 
the PET measurement method. The PET measurement method, however, requires the 
activation of pure 12C and 16O phantoms to determine α, β, α', β', γ' and hence 
calculate the 12C and 16O elemental fraction in the 12C+16O phantom. The Monte 
Carlo method on the other hand does not require this information since the 
corresponding α, β, α', β', γ' can be obtained directly from Monte Carlo simulation. 
The Monte Carlo method was developed particularly for patient tissue element 
decomposition because only 1 measurement (patient proton activation and PET scan) 
is feasible in patient studies. 
 
Both elemental decomposition methods (the PET measurement and Monte 
Carlo methods) estimated the fraction of 12C and 16O within a 3.6% difference, 
compared to the actual percentage for both beams over the depths of 0–8 cm. 
Regression analysis was performed on all intermediate (12C and 16O phantoms) and 
final (12C + 16O phantom) processes and their goodness of fit (R2) were equal to or 
greater than 0.992 in all 10 PET volumes (figures 3.6 and 3.7).  
 
Table 3.3 shows the elemental composition of 12C and 16O in 4 ROIs drawn 
in patient 1 (figure 3.8(a)) and a comparison with the ICRU 46 data. Standard 
deviation of measurement in each ROI is the same for both 12C and 16O since 12C 
fraction is a complement 16O fraction. Table 3.4 reveals the same results for the 4 
ROIs drawn in patient 2 (figure 3.9(a)) and the ICRU 46 data. For patient 1, short 
and delayed long PET scans were overlaid on the CT image (figures 3.8(a) and (b)). 
The calculated relative fractions of 16O and 12C for the same axial slice are shown in 
figures 3.8(c) and (d). The 2D map representing the goodness of fit (R2) between 
each PET voxel time activity curve and its corresponding fitted activity curve is 
shown in figure 3.8(e). Over 95% of the PET voxel shows R2 greater than 0.7 which 
represent good fits. A raw PET decay curve of a PET voxel and its fitting are shown 
as an example in figure 3.8(f). Similar results for patient 2 are shown in figures 3.9(a) 
– (f).  
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(a) 
 
 
(b) 
Figure 3.7 Monte Carlo method. (a) Estimated 12C and 16O (atomic) fractions at each 
phantom depth for a near monoenergetic beam. Actual percentages are shown as straight 
lines (refer to table 3.1). (b) Estimated 12C and 16O (atomic) fractions at each phantom depth 
for a SOBP beam. Actual (atomic) percentages are shown as straight lines. Error bars 
represent standard error at 95% confidence interval. 
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Table 3.3 Patient 1: Calculated elemental compositions vs. ICRU 46 data for 4 ROIs.  
 
 Elemental composition (% by atomic fraction) 
 Calculation ICRU 46 Difference 
 Average Standard 
deviation (%) 
  
ROI 16O 12C 16O 12C (%) 
Adipose tissue 1 36.7 63.3 6.1 34.0 66.0 2.7 
Adipose tissue 2 21.4 78.6 4.0 34.0 66.0 12.6 
Brain 1 61.7 27.8 7.7 78.6 21.4 6.4 
Brain 2 65.9 34.1 12.1 78.6 21.4 12.7 
* The difference was calculated by subtracting true percentage fractions with estimated 
fractions. 
 
 
Table 3.4 Patient 2: Calculated elemental compositions vs. ICRU 46 data for 4 ROIs.  
 
 Elemental composition (% by atomic fraction) 
 Calculation ICRU 46 Difference 
 Average Standard 
deviation (%) 
  
ROI 16O 12C 16O 12C (%) 
Vitreous humor 95.5 4.5 4.5 98.5 1.5 3.0 
Adipose tissue/ 
face mask 7.7 92.3 10.8 - - - 
Adipose tissue 
only 20.9 79.1 10.2 34.0 66.0 13.1 
Brain 63.4 36.6 8.5 78.6 21.4 15.2 
* The difference was calculated by subtracting true percentage fractions with estimated 
fractions. 
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Figure 3.8 Patient 1: (a) Short PET scan (0-5 minutes) overlaid on top of axial CT image, 4 
ROIs are drawn. (b) Delayed long PET scan (15-45 minutes), proton beam direction is 
shown. (c) 16O relative fraction map. (d) 12C relative fraction map. (e) 2D map of goodness 
of fit (R2). (f) PET decay curve of a PET voxel and its fitting using the least squares method. 
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Figure 3.9 Patient 2: (a) Short PET scan (0-5 minutes) overlaid on top of axial CT image, 4 
ROIs are drawn. (b) Delayed long PET scan (15-30 minutes), proton beam direction is 
shown. (c) 16O relative fraction map. (d) 12C relative fraction map. (e) 2D map of goodness 
of fit (R2). (f) PET decay curve of a PET voxel and its fitting using the least squares method. 
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The 12C and 16O fractions calculated from the 7 ROIs in the patient studies showed 
good agreement with the ICRU data (tables 3.3 and 3.4). For patient 2 (figure 3.9), 
the 16O fraction map constructed using the least-squares method was similar to the 
short PET scan. In addition, the 12C map for this patient was also quite similar to the 
delayed long PET scan. In this regard, one could suggest that short and delayed long 
PET scans can be used to show the fractional distribution of 16O and 12C. However, 
such a suggestion is flawed because a 16O-rich tissue region that is strongly activated 
by protons will have strong15O signals while another 16O-rich tissue region that is 
weakly activated by protons will have weak 15O signals and hence would not reflect 
its corresponding 16O-rich content. Therefore, short or delayed long PET scans 
which depend on the magnitude of activation cannot be used to determine the 16O 
and 12C elemental fractions. Our proposed method of elemental decomposition, on 
the other hand, can provide 16O and 12C fraction information, regardless of the 
regional activation magnitude, because the maps are constructed from decay schemes 
rather than from absolute PET signal magnitudes. As an example, for patient 1 
(figure 3.8), the difference between the short and delayed long scans is not clear 
because they are strongly dependent on the absolute magnitude. 
 
The results of the goodness of fit (R2) of the patient studies are worse than 
those for the phantom study. This is not surprising considering the volume of PET 
voxels for patient studies were 20 times smaller than for the phantom study. The 
difference in voxel volume is also reflected in the smoothness of the raw PET decay 
curves of the phantom study (figure 3.4) as compared to the large fluctuation (figures 
3.8(f) and 3.9(f)) seen in the patient studies. Although the model equation as well as 
its fitting is satisfactory, the large variance from this fluctuation resulted in lower R2 
values in patient studies compared to the phantom studies. PET signal averaging with 
adjacent voxels reduced this fluctuation and on average provided better goodness of 
fit over the large patient volume. The goodness of fit for patient 1 was worse than 
that of patient 2. This is partly due to a lower PET signal threshold for patient 1 (8% 
of maximum) than patient 2 (20% of maximum). When the PET signal threshold was 
increased, the goodness of fit improved (data not shown). (Excerpted from Cho et al 
2013a) 
 
3.4 Discussions 
 
In this research, a technique that decouples positron emission decays after proton activation 
into their constituent elemental composition has been developed. Using this technique, the 
goals of Specific Aim I have been successfully accomplished. The elemental composition of 
a phantom composed of 12C and 16O were estimated within a 4 % uncertainty using two 116 
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MeV proton beams over 8-cm depth range. Both Monte Carlo simulation and PET imaging 
studies show similar agreements to the actual composition. Patient studies show a mean 
(maximum) difference of 9.4% (15.2%) for 7 regions of interest (ROIs) when compared 
with the ICRU 46 data. These results show much the potential of the proposed technique in 
providing patient specific elemental composition to improve stopping power calculation as 
well as proton therapy (dose) verification using PET. 
This method was demonstrated for 2 elements (12C and 16O) in a phantom and soft 
tissue regions and therefore is a feasibility study. Attempts to analyze 12C and 16O fractions 
in non-soft tissue regions (for example, bone) may increase the uncertainty because 31P and 
40Ca activation have to be included, since both exist in large quantities in bone. Along the 
same line, the proposed method can be extended to analyze and determine the fractions of 
more elements, such as 14N, 31P, and 40Ca, but it is expected to be less accurate because the 
accuracy of the least-squares method decreases with the increasing number of elements. 
However, Schneider et al 2000 correlated CT numbers with elements such as H, N, P, and 
Ca within a few percent uncertainties. Therefore, Schneider’s method can be complemented 
to determine the elemental compositions other than 12C and 16O in tissues. In this research, 
evaluating 12C and 16O only is justified in soft tissue because the fraction of other proton-
activated elements (N, Na, P, S, Cl, and K) is quite small (3%-4%) (ICRU 46, Woodard and 
White 1986).  
There are several practical limitations of the proposed technique. First, it requires an 
in-room or on-site PET scanner due to the fast-decaying nature of the radioisotopes which 
can be costly for many proton therapy centers. Second, the technique depends on the 
accuracy of the washout model. While we used only an organ dependent biological washout 
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model (Mizuno et al 2003, Tomitani et al 2003, Parodi et al 2007b, 2008), it is well known 
that each organ shows different washout rates within the same organ (washout 
heterogeneity) and different isotopes suffer different washout rates (isotope specific 
washout) (Graffman S and Jung B 1975, Hughes et al 1979, Nussbaum et al 1983). 
Uncertainties in the washout model used in this research are the main source of error in 
elemental composition calculation. An isotope specific washout model which also considers 
washout heterogeneity will be ideal for more accurate elemental composition calculation, 
however, such a model has not been proposed yet. Third, this technique is dependent on the 
accuracy of the least squares method in separating the raw PET decay curve into its 
constituent tissue elements. The robustness of the proposed approach against fluctuations in 
PET raw decay curves should be the focus of future studies. Fourth, the accuracy of the 
proposed method is subject to the uncertainty of the cross section data. More accurate and 
universally accepted cross section measurement and data are required for more accurate 
elemental composition calculation. In this work all cross sections data used for the Monte 
Carlo simulations were obtained from Nishio et al 2005, 2008, which is in agreement with 
the experimental data (Iljinov et al 1994) available at the EXFOR library from Brookhaven 
National Laboratory National Nuclear Data Center 
(http://www.nndc.bnl.gov/exfor/exfor00.htm). 
Ideal treatment plans can be performed using the information of both patient specific 
electron density and patient specific elemental composition. The elemental composition can 
vary significantly between individuals (ICRU Report 46); hence, the average elemental 
composition of each organ should not be generalized across the patient population. In this 
regard, the best solution is to determine individual patient elemental tissue composition in 
  
38 
 
the entire treatment region in the same way that individual HU information is provided by 
CT. However, the proposed method could not provide information in the region where PET 
signals are relatively weak. More sensitive PET scanners are expected to provide more 
accurate elemental composition over a larger irradiation area. 
In practice, we envision each patient immediately after the first treatment receives a 
PET scan which provides the patient elemental tissue composition information using the 
above technique. The obtained elemental tissue composition information can then be used to 
refine the treatment plan and improve treatment (dose) verification using PET. Also, the 
elemental composition of tissues may change over the course of treatment due to, for 
example, the change of oxygenation and radiation induced necrosis – these changes of tissue 
elemental composition may be used to assess the treatment response. Future studies will 
address these problems as well as sensitivity of the proposed method on different tissues and 
biological washout. To our knowledge, this is the first investigation of the use of PET 
imaging to determine elemental tissue composition after proton therapy. 
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Chapter 4 
Feasibility of Proton-Activated Implantable Markers for Proton Range 
Verification using PET 
__________________________________________________________________________ 
With permission of IOP (Institute of Physics) Publishing, this chapter is based on the 
following article: Cho J, Ibbott G, Gillin M, Gonzalez-Lepera C, Titt U, Paganetti H, Kerr M 
and Mawlawi O 2013 Feasibility of proton-activated implantable markers for proton range 
verification using PET Phys. Med. Biol. 58 7497-7512. 
 
4.1 Introduction  
 
In the previous chapter, we investigated the method of obtaining elemental tissue 
composition information for the purpose of improving stopping power calculation and dose 
verification using PET. In this chapter, we will focus on a method of improving proton range 
verification using PET. Several investigators suggested imaging proton-activated tissues 
using a PET scanner for proton range verification (Paans and Schippers 1993, Oelfke et al 
1996, Nishio et al 2005, Crespo et al 2006, Parodi et al 2007a, 2007b, Knopf et al 2008, 
Nishio et al 2008, Zhu et al 2011). However, the verification of the proton range from tissue 
activation alone is difficult for a number of reasons. First, most elements in human tissue 
require relatively high proton energies to be activated (Litzenberg et al 1999) and, therefore, 
are minimally activated near the distal dose fall-off region of the proton beam, which limits 
the accuracy of proton beam range estimation using PET. Second, radioisotopes created in 
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activated tissues tend to diffuse and perfuse away from the proton interaction point 
(Tuckwell and Bezak, 2007, Parodi et al 2007b), which causes PET images to be distorted 
away from the proton activation region. Third, the radioisotopes created by tissue activation 
decay relatively quickly, necessitating an in-beam, in-room or at least an on-site PET 
scanner, which can be cost-prohibitive or technically challenging for many centers (Shakirin 
et al., 2011, Min et al., 2013).  
Because of these drawbacks, current in vivo proton therapy range verification using 
PET is supplemented by Monte Carlo simulations to compare with direct PET 
measurements. However, this approach has also been shown to have many limitations 
including the lack of reliable nuclear cross-section data (España et al 2011), tissue elemental 
composition uncertainty (Schneider et al 2000, Cho et al 2013a) and dependable biological 
washout rate models (Parodi et al 2007b, Knopf et al 2009, Knopf et al 2011). Therefore, a 
reliable in vivo proton therapy verification method that is not subject to the above limitations 
is desired.  
As noted earlier, the elemental composition and other characteristics of human tissue 
limit the ability to accurately determine the proton beam range. However, some stable 
isotopes of elements, including O, Cu, and Zn, have large proton nuclear interaction cross-
sections ranging from several hundred to more than 1000 mb (EXFOR library). Furthermore, 
the interaction energy thresholds of these isotopes is only a few MeV (which equates to a 
sub-millimeter proton residual range), which could potentially allow PET imaging to 
estimate the end of the proton beam range (figure 4.1, table 4.1). In addition, the 
radioisotopes created by these nuclear interactions decay with relatively long half-lives (tens 
of minutes). Therefore, when inserted or infused into the target volume, these markers could 
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potentially be used to verify the proton beam range with an off-site PET scanner (Cho et al 
2009, Cho et al 2011).  
In this study, we investigated the feasibility of using implantable markers for proton 
range verification by testing whether stable isotopes such as 18O, 63Cu, and 68Zn would 
produce a sufficiently large signal at the distal dose fall-off region to reliably determine the 
proton beam range using PET imaging. We also investigated the relationship between the 
dose fall-off and the proton activation. Tissue-equivalent materials were irradiated alongside 
the candidate materials for comparison. Our investigations were conducted for candidate 
materials that were directly irradiated or embedded in tissue-equivalent phantoms. 
 
4.2 Materials and Methods  
 
4.2.1 Experimental setup 
We examined three candidate stable isotopes as implantable markers: 18O, 63Cu, and 
68Zn. All candidate isotopes had three common characteristics: a large proton 
interaction cross-section, a low interaction energy threshold, and a relatively long 
half-life (figure 4.1, table 4.1). The three candidate materials used in our 
investigation were: ≥98% 18O-enriched water, natural Cu foils (natural abundance: 
69.15% 63Cu, 30.85% 65Cu), and 97.8±0.2% 68Zn-enriched foils (which we refer to 
as >97% 68Zn). We also chose tissue-equivalent materials containing 16O and 12C 
(such as water (99+% H216O), 99+% heptane [12C7H16], and polycarbonate 
[12C16H1416O3]n) for comparison. These tissue equivalent materials were chosen since 
16O and 12C are responsible for more than 95% of tissue activation in typical patient 
proton treatments (Litzenberg et al 1999). 
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Figure 4.1 Proton nuclear interaction cross-sections of tissue-equivalent elements 12C and 
16O, as well as candidate elements 18O, 63Cu, and 68Zn, that produce positron-emitting 
isotopes (http://www.nndc.bnl.gov/exfor/exfor00.htm)  
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Table 4.1 Characteristics of the four most abundant proton-induced reactions in tissue that 
result in positron decay, along with characteristics of candidate elements. 
 
Reaction  
of  
elements 
Maximum 
interaction 
cross-
section, 
mb/MeV 
Interaction 
threshold 
energy, 
MeV 
Proton beam 
range in 
tissue below 
threshold 
energy, mm 
Proton beam 
range below 
maximum 
cross-section, 
mm 
Half-life 
of 
radio-
isotope, 
minutes 
 
Tissue-equivalent      
12C(p,pn)11C 96/45 20.3 4.0 18.4 20.3 
16O(p,pn)15O 71/53 16.6 3.0 24.7 2.0 
16O(p,α)13N 50/12 5.5 0.4 1.7 10.0 
16O(p,αpn)11C 19/63 27.5 8.0 33.7 20.3 
 
Candidate      
18O(p,n)18F 502/5 2.6 0.1 0.4 109.8 
63Cu(p,n)63Zn 546/11 3.9 0.2 1.5 38.5 
68Zn(p,n)68Ga 1070/11 3.4 0.2 1.5 67.7 
Iljinov et al 1994, Nishio et al 2008; http://www.nndc.bnl.gov/exfor/exfor00.htm 
 
Two groups (direct irradiation and embedded irradiation) of experiments 
were conducted in this research. In each group, 2 experiments were performed. In the 
direct irradiation group, the candidate materials were directly irradiated and then 
PET imaged. In the embedded irradiation group, the candidate materials were first 
embedded in tissue equivalent materials such as Plastic Water® and balsa wood and 
then irradiated before being imaged with the PET scanner. The setups for each of the 
4 experiments are summarized in Table 4.2. 
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Table 4.2 Sample irradiation and positron emission tomography (PET) scan setup for each 
experiment. 
 
Group 
Measurement 
Direct Irradiation Embedded Irradiation 
Experiment First Second First Second 
Dose, Gy 10.0 12.5 12.5 12.5 
90% range, mm 108 110 110 110 
SOBP, cm  6 10 10 10 
Field size, cm × cm 18 × 18 25 × 25 10 × 10 10 × 10 
Irradiation time, minutes 8.0 15.4 4.0 4.5 
Candidate material 
18O-enriched 
water 
68Zn foils,  
Cu foils 
68Zn foils,  
Cu foils 
68Zn foils,  
Cu foils 
Candidate material volume, 
mm3 
2000 10 50 50 
Tissue-equivalent material 
Water, 
heptane 
Poly-
carbonate 
Plastic 
Water® 
Balsa 
wood 
Tissue-equivalent material 
volume, mm3 
2000 76 500000 1000000 
Depth 1, mm/PDD, % 108/87 106.5/99.6 106.5/99.6 106.5/99.6 
Depth 2, mm/PDD, % 110/49 108.5/97.4 108.5/97.4 108.5/97.4 
Depth 3, mm/PDD, % 112/15 110.5/79.2 110.5/79.2 110.5/79.2 
Depth 4, mm/PDD, % 113/6 112.5/38.7 112.5/38.7 112.5/38.7 
Delay time, minutes 35 50 95, 155 50 
PET scan time, minutes 20 30 180 30 
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4.2.1.1 Direct irradiation 
 
For both experiments in this group, we stacked slabs of water-equivalent (with 
respect to proton stopping power) plastic phantoms (Plastic Water®; CNMC, 
Nashville, TN) in four columns of different heights on top of the proton treatment 
couch (figure 4.2(a)). On top of each column, we placed samples of candidate 
materials and tissue-equivalent materials. After accounting for the thickness of the 
treatment couch and container (for liquid samples), the location of the samples 
corresponded to 4 different water-equivalent depths at the distal dose fall-off region 
(100% ~ 3% of COM dose) of the proton beam (figures 4.2(b)). The setup was then 
irradiated from below the treatment couch using a passively scattered 160-MeV 
proton beam (Hitachi PROBEAT, Hitachi city, Japan) at The University of Texas 
MD Anderson Cancer Center Proton Therapy Center in Houston, Texas. A 
modulated proton beam of 6-cm and 10-cm spread-out Bragg peak (SOBP), with a 
field size of 18 × 18 cm2 and 25 × 25 cm2 for the first and second experiment 
respectively was used to generate a laterally uniform beam to irradiate all the 
samples. 
For the first experiment in this group, we tested whether the activation of 18O 
produces a stronger signal than that of endogenous tissue elements (16O and 12C). We 
used 2-ml samples of ≥98% 18O-enriched water (Matheson, Montgomeryville, PA), 
99+% 16O water (distilled water), and 99+% heptane. Each 2-ml sample was placed 
in a cylindrical polystyrene petri dish with an inner diameter of 3.6 cm, which made 
each sample 2 mm thick when poured into the petri dish. One empty petri dish was 
additionally placed at each depth for background measurement, and the samples at 
the four different depths were irradiated to a dose of 10 Gy. The irradiated samples 
(3 samples + 1 empty at each depth) in petri dishes were then moved to an off-site 
PET/CT scanner (Discovery PET/ computed tomography (CT) 690 scanner, GE 
Healthcare, Waukesha, WI) at the MD Anderson Center for Advanced Biomedical 
Imaging, which is located approximately 300 meters from the Proton Therapy Center. 
A PET scan was then acquired for 20 min after a delay of 35 min. 
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(a) 
 
(b) 
Figure 4.2 Setup for direct irradiation. (a) Water-equivalent plastic phantoms (Plastic 
Water®) were stacked to different depths in four columns on top of the treatment couch. The 
four petri dishes on top of each column contained 99+% heptane (12C), 99+% 16O water, ≥98% 
18O-enriched water, and blank (empty dish). A 160-MeV proton beam irradiated the samples 
from below. (b) Locations of the samples on the four columns of water-equivalent plastic 
phantoms overlaid on the percentage depth dose (PDD) curve of the proton beam. Samples 
were irradiated at four different depths along the distal fall-off.  
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The second experiment in this group was performed to compare the 
activation of two other proposed candidate isotopes (63Cu and 68Zn) with a tissue-
equivalent material. An identical setup was used as the first experiment (figure 4.2); 
however, 0.10 mm-thick natural Cu foils (Nimrod Hall Copper Company, 
Springfield, VA; density = 8.96 g/cm3) and 0.10 mm-thick >97% 68Zn-enriched foils 
(Trace Sciences International, Richmond Hill, Ontario, Canada; density = 7.14±0.50 
g/cm3) were used as candidate materials. Natural Cu foils were used because 63Cu’s 
natural abundance is relatively high (69.15%). In addition, 0.76 mm-thick 
polycarbonate sheets (density = 1.22 g/cm3) were used as a tissue-equivalent material. 
The water-equivalent thickness of polycarbonate sheets was approximately the same 
as Cu and 68Zn-enriched foils (about 1 mm), so all samples were activated by the 
same proton energy fluence. All samples were cut into squares 1 cm × 1 cm, yielding 
volumes of 10 mm3, 10 mm3, and 76 mm3 for 68Zn-enriched foils, Cu foils, and 
polycarbonate sheets, respectively. Two samples of each material were placed at 
each of 4 different depths over the distal dose fall-off region and were irradiated with 
a dose of 12.5 Gy to the COM. The irradiated 68Zn-enriched foils, Cu foils, and 
polycarbonate sheets were then moved to the same off-site scanner and scanned for 
30 min after a delay of 50 min.  
 
 
4.2.1.2 Embedded irradiation 
 
Two experiments were performed in this group as well. In the first experiment, two 
types of foil stacks (Cu and 68Zn) were used. Each stack was composed of five 1 × 1 
× 0.01 cm foils (Cu or 68Zn) placed on top of one another. This process resulted in a 
volume of 50 mm3 which ensured a large activation signal. A total of four stacks of 
Cu and two stacks of 68Zn (due to limited availability of 68Zn foils) were made. The 
Cu and 68Zn stacks were then embedded in slabs of Plastic Water® (as a soft-tissue 
replacement) at four different depths of the distal dose fall-off range and irradiated 
(figure 4.3). To obtain 68Zn activation at 4 different depths out of two available 
stacks, two repeat experiments were performed. Repeat experiments were performed 
with one week interval to allow enough time for activated 68Zn foils to decay. A 
modulated proton beam (10-cm SOBP) with a field size of 10 × 10 cm2 was used to 
deliver 12.5 Gy to the samples. The activated phantoms with embedded samples 
were then moved to the off-site scanner for PET/CT scanning. A much longer delay 
and PET scan duration were required for this experiment due to the high background 
signal from Plastic Water®. This high background is mainly from high 12C (46.7% 
of mass fraction composition) of Plastic Water®. Its complete elemental composition 
is shown in Ramaseshan et al., 2008.  
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Figure 4.3 Setup for imbedded irradiation. 68Zn and Cu foils at a volume of 1 × 1 × 0.05 cm 
were sandwiched between Plastic Water® at four different distal dose fall-off depths. 
Phantom was irradiated using a 160 MeV proton beam. 
 
 
 
The setup of the second experiment in this group was identical to the first 
experiment (figure 4.3) except for using a high-density (~ 0.3 g/cm3) balsa wood 
(Turner Toys, Essex Junction, VT) phantom as a human lung replacement (average 
density ~ 0.3 g/cm3) instead of Plastic Water®. Cu foils were placed at all 4 depths 
while 68Zn foils were placed at depths 2 and 3 only. No repeat experiment was 
performed in this case to place the 68Zn stacks at depths 1 and 4. The depths of each 
sample in balsa wood were determined from CT simulation followed by treatment 
planning performed using a Varian Eclipse™ treatment planning system (Palo Alto, 
California). The activated phantom with samples was then moved to the off-site 
scanner and scanned for 30 min after a delay of 50 min. The chemical composition 
of balsa wood (Ochroma lagopus) is shown in Sjŏstrŏm E 1981 and 12C also 
comprises about 50% of mass.  
 
All PET data in the four experiments were acquired without decay correction. 
The mean and standard deviation of the activation signal intensity in the candidate 
material was then measured in regions of interest drawn on the corresponding PET 
images. The normalized percentage of activity (normalized to maximum activity) for 
each sample was then compared with the percentage depth dose (PDD) curve in the 
distal dose fall-off region. The PDD data used for comparison is based on the 
commissioning data which also agrees with the most recent annual data (2012). 
However, the accuracy of the data was checked by point Markus ionization chamber 
measurements prior to each experiment throughout this research. For the liquid 
samples (direct irradiation group, first experiment), background signal was 
calculated from the image of an empty petri dish and was subtracted from the signals 
from each of the liquid samples.  
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For all PET imaging procedures, the samples were separated by more than 1 
cm to minimize the impact of partial volume effects. Each depth/PDD value in table 
4.2 represents the middle depth of the sample and the PDD in the middle of the 
sample. All depths are water equivalent depths. 
 
 
4.2.2 Monte Carlo simulation 
 
Monte Carlo simulations were performed for two purposes. The first purpose was to 
find the PDD depths at which candidate materials should be placed to obtain 
adequate signal for proton range verification. The second purpose was to compare 
the Monte Carlo-simulated relative signal intensities of candidate materials to those 
of the tissue-equivalent materials over the distal dose fall-off region in both 
experiments of the direct irradiation group. A modulated SOBP proton beam 
delivered by a double-scattering system was simulated. The beam line model was 
validated by Titt et al (2008) using the MCNPX Monte Carlo code (Waters et al 
2005) and was based on blueprints of the MD Anderson Cancer Center proton gantry 
and nozzle provided by the manufacturer (Hitachi Ltd., Hitachi city, Japan). This 
model was used to generate a PDD curve in a water phantom. The Monte Carlo-
generated PDD curve was matched with measurement data at the distal 90% dose 
depth. The distal 90% – 10% dose fall-off region agreed with the commissioning as 
well as annual measurements to within ± 0.2 mm (± 4% dose). This agreement was 
necessary because the accuracy of the location and shape of the distal dose fall-off 
region was crucial for this study. Particle information for the transported protons, 
such as particle fluence and its energy distribution (particle energy fluence), was 
scored at several depths within the distal dose fall-off region. To calculate the proton 
induced activation of different samples, the product of published cross-section data 
and the proton energy fluence (MCNPX tally type 4) at each depth was integrated. 
Activity contributions from secondary neutrons were ignored in this calculation for 
simplicity, because the secondary neutron fluence was small compared to the total 
number of protons. Furthermore, the probability of producing positron emitters is 
smaller for neutrons than it is for protons. Details of the Monte Carlo simulation 
technique were described by Seravalli et al (2012)), whose MCNPX activity 
simulation was followed. All cross-sections used here were from experimental data 
available in the EXFOR library (http://www.nndc.bnl.gov/exfor/exfor00.htm). 
(Excerpted from Cho et al 2013b) 
 
4.3 Results 
 
PET images obtained from the first experiment of the direct irradiation group are 
shown in figure 4.4(a).The normalized activity in the samples placed at the proton 
  
50 
 
beam distal fall-off depths is tabulated in table 4.3 and also shown in figure 4.4(b). 
The vertical error bars represent standard error computed with 95% confidence limits. 
The uncertainty in the distal dose fall-off location of the beam, which is shown as 
horizontal error bars, was on the order of ±1 mm which is equivalent to the standard 
error of the commissioning data. The relationship between the percentage of proton 
activity in 18O water and depth followed closely the distal dose fall-off curve with an 
offset less than 1 mm. The Monte Carlo simulations agreed with measured activity 
within 5% difference for all three samples (figure 4.4(b)).  
 
 
Table 4.3 Direct irradiation – first experiment: Percentage activity (mean ± standard error) 
per unit volume for 18O-enriched water, 16O water and heptane at 4 different distal fall-off 
depths. Errors in 95% confidence limits. 
 
 
                          Percentage Activity (%) 
Depth PDD 18O-enriched water 16O water Heptane 
Depth 1 96 – 70 % 100 ± 23 % 7 ± 2 % < 1 % 
Depth 2 70 – 30 % 59 ± 14 % < 1 % < 1 % 
Depth 3 30 – 6 % 12 ± 3 % < 1 % < 1 % 
Depth 4 15 – 3 % 3 ± 1% < 1 % < 1 % 
 
 
PET images from the second experiment of the direct irradiation group are 
shown in figure 4.5(a). PET signals from the polycarbonate sheets were comparable 
to those from 68Zn and Cu foils, despite the fact that the polycarbonate volumes were 
7.6 times greater than those of the 68Zn and Cu foils. The polycarbonate sheets show 
a strong activity signal only at depth 1 while 68Zn and Cu foils show relatively strong 
activity till depth 3. PET signals were normalized to a unit volume and overlaid on 
the PDD profile at the distal dose fall-off depth (figure 4.5(b)). The activities per unit 
volume at four distal fall-off depths are tabulated in table 4.4 and also shown in 
figure 4.5(b). The change in activity of 68Zn and Cu with depth resembled the change 
in dose, with offsets of approximately 1 and 2 mm, respectively. Monte Carlo 
simulations agreed with measurements with a mean difference of 7% (figure 4.5(b)); 
however, the measured polycarbonate activation was consistently higher (max 
difference of 23%) than the Monte Carlo-simulated polycarbonate activation.  
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(a) 
 
(b)  
Figure 4.4 Direct irradiation – first experiment. (a) PET/CT fusion images of petri-dishes 
containing nothing (empty), heptane (12C), 18O water, 16O water are arranged along the 
various depths. (b) PET signals from each sample were quantified and overlaid on the PDD 
curve of the proton beam. Vertical error bars represent the standard error with 95% 
confidence limits. Monte Carlo results are shown for comparison.  
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(a) 
 
 
(b) 
Figure 4.5 Direct irradiation – second experiment. (a) PET/CT fusion images from the 
polycarbonate sheets (PC), 68Zn and Cu foils are arranged along the different depth locations. 
(b) PET signals per unit volume were quantified and overlaid on the PDD curve of the 
proton beam.  
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Table 4.4 Direct irradiation – second experiment: Percentage activity (mean ± standard error) 
per unit volume for 68Zn-enriched foil, Cu foil and polycarbonate at 4 different distal fall-off 
depths. Errors are in 95% confidence limits. 
 
 
                          Percentage Activity (%) 
Depth PDD 68Zn-enriched foil Cu foil Polycarbonate 
Depth 1 100 – 99 % 80 ± 28 % 67 ± 16 % 30 ± 2 % 
Depth 2 99 – 95 % 100 ± 21 % 91 ± 16 % 8 ± 5 % 
Depth 3 87 – 71 % 68 ± 6 % 32 ± 19 % 2 ± 1 % 
Depth 4 49 – 29 % 2 ± 2 % 17 ± 1 % < 1 % 
 
 
 
It was observed that the measured activity from polycarbonate sheets was 
consistently greater than the Monte Carlo-simulated activity (Figure 4.5(b)). This 
could be attributed to the higher kinetic energies of positrons from 68Zn and Cu 
progeny radioisotopes (~ 1 MeV) compared to those from 11C (385.7 keV) (EXFOR 
library). Alternatively, the smaller thickness of foils compared to polycarbonate 
sheets could cause more positrons to escape from the foils than from the 
polycarbonate sheets thereby resulting in a lower PET signal. 
 
Figure 4.6 shows PET/CT fusion images from the first experiment of the 
embedded irradiation group (50 mm3 samples irradiated with 12.5 Gy using a 10 × 
10 cm2 beam). Figures 4.6(a) – (d) are from the first image reconstruction – a 95-min 
post-irradiation delay followed by a 3-hr scan. Figures 4.6(e) and (f) are from the 
second image reconstruction – a 155-min post-irradiation delay followed by a 3-hr 
scan. Figures 4.6(a), (b), and (e) show the activation of the phantom and foils with a 
beam’s-eye view. Figures 4.6(c), (d), and (f) show a lateral view of activation, with 
the proton beam incident from below. For the first image reconstruction, activation 
of the 68Zn foils is seen at depths 1 – 3 but not depth 4 (figure 4.6(a) – (d)). 
Activation of the Cu foils was seen only for depth 1 and only after a much longer 
delay of 155 min (figure 4.6(e) and (f)). This result is probably due to the higher 
interaction cross-section of 68Zn and the longer decay half-life of its progeny 
radioisotopes compared to Cu. 
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Figure 4.6 Embedded irradiation – first experiment. 68Zn and Cu foil samples (50 mm3) 
were sandwiched in four different depths of Plastic Water® and were proton activated and 
PET/CT fusion images are shown. (a) Beam’s-eye view of depths 1 and 2 for 68Zn and Cu. 
(b) Beam’s-eye view of depths 3 and 4 for 68Zn and Cu. (c) & (d) Lateral views for 68Zn. (e) 
Beam’s-eye view of depth 1 for Cu. (f) Lateral view for Cu at depths 1 and 2. Image 
reconstruction conditions for (a), (b), (c), and (d) were a 95-min delay followed by a 3-hr 
scan; (e) and (f) were obtained with a 155-min delay followed by a 3-hr scan.  
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Figure 4.7(a) – (f) shows PET/CT fusion images from the second experiment 
of the embedded irradiation group. The phantom was irradiated by 12.5 Gy, and PET 
scanning lasted for 30 min after a 50-min delay. All irradiated foils were strongly 
activated. The relatively weaker activation of Cu at depth 4 indicated the distal 
margin of the proton activation. The location of each depth is shown relative to the 
isodose curves created from a CT simulation is shown in figure 4.7(g). 
 
A longer PET scan duration (3 hr) was required (figure 4.6) for 68Zn and Cu 
foils embedded in Plastic Water® than in balsa wood to be imaged above the 
background signal. A typical 30 min PET scan did not provide enough SNR for 68Zn 
and Cu foils due to the high background signal. The high background signal from the 
phantom was mainly due to the high 12C content (mass 12C fraction: 46.7%, physical 
density: 1.039 g/cm3) of Plastic Water® (Ramaseshan et al., 2008). For the same 
volume of 68Zn and Cu foils embedded in balsa wood, activation was much stronger 
than the background, although the phantom and inserts were scanned for only 30 min. 
This result was mainly due to the lower background signal coming from the balsa 
wood’s lower physical density (~ 0.3g/cm3), despite having a high 12C fraction 
(~50%). Both Plastic Water® and high density balsa wood are not ideal tissue-
equivalent materials in activation studies due to their higher 12C content. The average 
12C mass fraction in soft-tissue is typically less than 20% (ICRU Report 46). 
 
Figures 4.7 (e) and (f) show the potential of this approach for proton range 
verification. While it is difficult to define the furthest activation depth from phantom 
(or patient tissue) activation alone, due to the gradual decrease of activity and the 
resultant increase in PET image noise, activation of implanted foils show the distinct 
end of activation at depth 4. By correlating the signal from implanted markers and 
the PDD, it is possible to estimate the proton range. (Excerpted from Cho et al 2013b) 
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Figure 4.7 Embedded irradiation – second experiment. Samples (50 mm3) sandwiched at 
four different depths (for Cu foils) and at depths 2 and 3 (for 68Zn foils) of balsa wood were 
proton activated and PET/CT fusion images are shown. (a) – (d) Beam’s-eye views of 
depths 1 – 4. (e) and (f) Lateral views. (g) Isodose curves are shown relative to each depth 
location. The phantom was irradiated by 12.5 Gy, and PET scanning lasted for 30 min after 
a 48-min delay.  
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4.4 Discussions 
 
In this research, we characterized the dose versus activation relationship at the distal fall-off 
region using three candidate materials - 18O enriched water, natural Cu foils, and 68Zn 
enriched foils using both PET measurements and Monte Carlo simulations. They all 
produced strong PET signals over the dose distal fall-off region compared to tissue-
equivalent materials fulfilling the goals proposed in Specific Aim II. We also activated Cu 
and 68Zn enriched foils embedded in tissue-equivalent phantoms and stronger PET signals 
resulted from the foils. This demonstrates that the candidate materials could possibly be 
used as implantable markers for proton beam range verification using PET. Once irradiated, 
the markers would be activated and would emit positrons with relatively long half-lives 
while most activated patient tissue would decay after tens of minutes due to their inherent 
short half-lives. This would allow a delayed PET scan to detect the strong signals only from 
the markers using an off-site PET scanner which is accessible for most proton centers. 
At a minimum 2 markers would be required to verify the proton range. One would be 
implanted proximally near the distal fall-off region (at a shallower depth) and the other 
distally (outside the field). These markers should be implanted with a separation along the 
direction perpendicular to the beam and a small offset in the beam direction to minimize 
beam-shadowing. When one proximal marker is activated and the other distal marker is not, 
it can be assumed that the proton beam stopped between the two fiducial marker depths. The 
CT images can help to distinguish the activated markers from the non-activated markers 
because CT and PET images are obtained sequentially in current PET/CT system. 
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The candidate materials tested in this work could be manufactured as biocompatible 
implantable markers that could serve as proton-activated markers. 18O enriched water is not 
toxic because it is biologically identical to 16O water. Also, Zn is an essential mineral in the 
body and has no known toxicity from moderate consumption. However, Cu has some known 
side effects such as fatigue, depression and skin reaction (Brewer 2010). Also a study by 
Tindel et al 2001 showed that small fragments of Cu that were surgically implanted on the 
spinal cords of rabbits caused a localized neural injury. However in cases where the toxicity 
of implanted elements is a concern, the implants can be coated with biologically compatible 
elements such as Ti to alleviate this concern. 
Monte Carlo simulation was only performed for the direct irradiation group of 
experiments to validate quantitatively the relative activity of candidate materials compared 
to tissue-equivalent materials. The same validation was not necessary for the experiments in 
the embedded irradiation group because the purpose of these experiments was primarily to 
demonstrate that the signals from the embedded candidate materials are strong enough to be 
visible despite the background signals from tissue-equivalent phantoms. 
With the exception of the first experiment in the embedded irradiation group, all PET 
scan times were 20 min or 30 min (with an exception of Plastic Water® embedded 
irradiation) which corresponds to the maximum patient whole body PET scan time. A 20 – 
30 min PET scan corresponds to a typical whole body eyes to thighs scan duration and is 
expected to be tolerable by patients. The scans were acquired at a different delay time to 
provide the maximum SNR compared to background signals from phantoms or tissue-
equivalent materials.  
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There are several advantages of the proposed approaches. These include the 
relatively high atomic numbers of some of the candidate materials (Cu and 68Zn), to also 
serve as radiographic fiducial markers when surgically implanted into the target or the distal 
organ (for example, the lung or the liver) prior to proton therapy. The proposed markers may 
replace radiographic fiducial markers with the added benefit of proton beam range 
verification. Another advantage of the proposed candidate materials is their minimal dose 
perturbation or shadowing. As reported by Cheung et al 2010 and Huang et al 2011, non-
gold fiducial makers have the advantage of significantly less dose perturbation compared to 
gold fiducial makers due to their smaller atomic numbers. The proposed materials (Cu and 
68Zn) have similar atomic numbers to the currently available non-gold fiducials makers and 
are expected to provide the same benefit.  
Thoracic SBRT patients can benefit greatly from this application due to the large 
daily dose as well as the large uncertainties in proton range calculation using the treatment 
planning system. Additionally, the SNR of the lung-implanted proton-activated markers is 
expected to be greater than our balsa wood experiment because the typical fraction of 12C in 
the lung is only around 10% (Woodard and White, 1986) while balsa wood is around 50%.  
There are some limitations to the use of implanted markers for proton range 
verification. These include the invasive nature of the procedure and the limited information 
achieved. Only a single or multiple point verification can be obtained rather than a 
volumetric proton range verification. Implanting more markers on the other hand will 
provide more volumetric proton range information, however this could increase organ stress 
due to multiple needle punctures. Implanting a small number of markers, however, can still 
satisfy some clinical needs; for example, by implanting only two markers in front of critical 
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organs such as the spinal cord, we can verify the proton range as well as the irradiation of 
that organ. Another limitation of this feasibility study includes our use of idealized samples 
(flat liquid samples and foils) and phantoms made of plastic or wood. Future studies should 
use representative shapes (eg., cylinder) that facilitate implantation in soft tissue or lung and 
the use of more realistic phantoms that include tissue heterogeneity. 
18O-enriched water was included in our experiment, although its application seems 
unlikely, unless it is encapsulated. However, despite other disadvantages including perfusion 
driven wash-out, oxygen offers the advantage of being a major component of human tissues. 
If consumed as 18O water or injected into the tissue region to obtain enough concentration, it 
can be used for proton range verification assuming 18O-enriched water can be obtained 
cheaply in the future.  
A relatively large dose (10 or 12.5 Gy) and volume (50 mm3 for imbedded 
irradiation) were used in this feasibility study to ensure a strong signal from the candidate 
materials. Although, 12.5 Gy is the daily dose used for thoracic stereotactic body radiation 
therapy (SBRT) patients at our institution, a 2 Gy daily dose (1 Gy per field) is more 
commonly used. Also, a typical mid-atomic numbered (non-gold) fiducial markers has a 
smaller size (about 10 mm3) than what was used in this feasibility study. The research 
presented in the following chapter (Specific Aim III) investigates the sensitivity of different 
volumes of candidate materials for more practical volumes (~ 10 mm3) and dose (~ 2 Gy). In 
other words, a characterization study was performed to determine the optimal volume of 
markers to provide adequate PET signals when irradiated by proton dose commonly used in 
the clinic as well as PET scan time tolerated by patients. 
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To the best of our knowledge, this is the first investigation evaluating the feasibility 
of implantable or infusible materials for in vivo proton beam dose and range verification 
using PET. Our results indicate that the 3 materials we studied—18O-enriched water, natural 
Cu foil, and 68Zn foil—could potentially be used for in vivo proton beam range verification.  
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Chapter 5 
Characterization of Proton-Activated Implantable Markers for Proton 
Range Verification using PET 
__________________________________________________________________________ 
 
 
 
5.1 Introduction 
 
The Specific Aim II study (Cho et al 2013b) discussed in the last chapter shows much 
potential of proton range verification using patient implantable fiducial markers; however, 
the markers’ volume used (≥ 50 mm3) was somewhat greater than the volume of typical 
fiducial markers (~ 10 mm3), and the dose (≥ 10 Gy) was greater than the typical dose (~ 2 
Gy) used in proton therapy. Furthermore, the phantoms used in that study (plastic water and 
high density balsa) were not good representatives of true patient tissue equivalents.  
Therefore, we report on characterization studies for different volumes (10, 20, and 50 
mm3) of Cu and 68Zn markers embedded in more tissue-like phantoms (low density balsa 
wood and beef) and irradiated using clinically relevant doses (1, 2, 3, and 5 Gy). Activated 
phantoms with embedded markers were imaged using an off-site PET scanner and 
reconstructed using various delay times to find the maximum signal-to-noise ratio (SNR). 
The purpose of this research (Specific Aim III) was to determine the optimal volumes of 
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these types of fiducial markers that give acceptable signals when irradiated by proton beams 
in a range of clinically relevant proton doses as well as a range of clinically relevant PET 
scan times. Delay times that gave the highest SNR were also determined for different 
combinations of phantom material and dose.  
Each set of PET/CT fusion images containing various volumes of Cu and 68Zn 
markers obtained using a different combination of dose, phantom and PET scan time was 
presented to 13 nuclear medicine clinicians and ROC studies were performed by scoring the 
visibility of each activated markers. From these ROC studies, optimal marker volumes were 
suggested which give acceptable PET signal (visibility) for different combinations of 
irradiated dose, phantom, and PET scan time. 
 
 
5.2 Materials and Methods  
 
5.2.1 Fiducial markers and phantom materials 
 
We examined two candidate material types as implantable markers: natural Cu foils and >97% 
68Zn-enriched foils. Both foils were 0.1 mm in thickness and cut into 10 × 10 mm. The 
characteristics of those materials are described in Cho et al (2013b).  
Two tissue substitute materials were used to simulate tissues in which markers were 
implanted: low-density (ρ ~ 0.1 g/cm3) balsa wood as a human lung tissue (ρ ~ 0.3 g/cm3) 
substitute; and beef (round eye, USDA grade, ρ ~ 1.0 g/cm3), as a unit density soft-tissue 
substitute. Although high-density balsa (ρ ~ 0.3 g/cm3) wood is commonly used as a lung 
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substitute in various dosimetry studies (Van Dyk et al 1982, Moyers et al 2010, Blatnica 
2011), low-density (ρ ~ 0.1 g/cm3) balsa wood was selected since it provided similar 
background PET signals as human lung tissue following proton activation. According to 
Monte Carlo simulations (results are not shown here), low-density balsa wood provided 
similar background PET signals as human lung tissues for the post-irradiation delay time 
used in this research. 
 
5.2.2 Group 1 experiments – Low-density balsa wood phantom irradiation 
 
For the group 1 experiments, three different volumes (10, 20, and 50 mm3) of copper 
markers were created by stacking one, two, and five 10 × 10 × 0.1 mm copper foils. In the 
same way, 10, 20, and 50 mm3 68Zn markers were created. In addition, two phantoms of 
24.1 × 10.2 × 10.3 cm were created for simultaneous planning and treatment, each by 
stacking eleven 24.1 × 10.2 × 0.94 cm low-density balsa wood (ρ ~ 0.1 g/cm3) slabs (figure 
5.1(a)). The two phantoms were placed on the CT couch next to each other and scanned. 
Phantoms were referred to as the superior and inferior phantoms according to their relative 
positions for CT scanning, planning, and treatment. The resultant CT images were used for 
treatment planning using an Eclipse treatment planning system (Varian Medical Systems, 
Palo Alto, California). Planning was performed using a 160-MeV scattered proton beam 
with a range of 11.0 cm (defined at 90% of the percentage depth dose [PDD]) that was 
modulated to 10 cm in width. A field size of 25 × 25 cm2 was used, and a 10.6-cm water 
phantom was created in the treatment planning system upstream of the balsa wood CT 
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images to simulate the actual proton irradiation setup. Dose was calculated and isodose 
curves were created on the balsa wood phantoms. 
After treatment planning, the copper markers were embedded between balsa wood 
slabs at 10 different depth locations (figure 5.1(a)), embedding a total of 30 markers in each 
phantom (10 depths × 3 volumes). Marker embedding was done after CT scanning to avoid 
creating artifacts on the CT images. Markers were placed so they would not beam shadow 
each other, with > 1-cm lateral margins. Because of the high cost and therefore limited 
availability of 68Zn foils, only one 10, 20, and 50 mm3 68Zn markers were embedded in the 
superior phantom at the depth 3 location (figure 5.1(a)). In the inferior phantom, only one 20 
mm3 68Zn marker was embedded, also at depth 3. The locations of embedded markers 
relative to the PDD of the proton beam are shown in figure 5.1(b). 
Three separate experiments (experiments 1 – 3) were performed using these 
phantoms in this group (table 5.1). For all experiments, superior and inferior balsa wood 
phantoms were placed next to each other on top of Plastic Water phantoms (Plastic Water 
Diagnostic Therapy (PWDT): CIRS, Norfolk, VA), on top of the treatment couch (figure 
5.1(a)). The setup was then irradiated from below the treatment couch using a passively 
scattered 160-MeV proton beam (PROBEAT; Hitachi, Hitachi-city, Japan) at The 
University of Texas MD Anderson Cancer Center Proton Therapy Center in Houston, Texas. 
The beam parameters were similar to those used in the treatment plan. 
For experiment 1, proton doses of 5 and 1 Gy were delivered consecutively to the 
superior and inferior phantoms, respectively; the upstream water-equivalent thickness 
(Plastic Water + treatment couch) was 106 mm. The depth for the 68Zn markers (depth 3) 
was 108 mm in water-equivalent thickness and 99% in PDD, while the depths for the Cu 
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markers (depths 1 –10) were 107 – 113 mm in water-equivalent thickness and 99 – 29% in 
PDD. For experiment 2, total proton doses of 3 and 2 Gy were delivered to the inferior and 
superior phantoms, respectively, with an upstream water-equivalent thickness of 108 mm. 
For experiment 3, 1 Gy was delivered simultaneously to both phantoms using two different 
upstream water-equivalent thicknesses for the 68Zn markers – 110 mm for the superior 
phantom and 106 mm for the inferior phantom. Although the maximum 68Zn activation 
occurs at a depth of 108 mm, depths 3 (106 – 110 mm) for 68Zn markers implantation were 
chosen with ± 2 mm variation over the broad high activation region (> 80% of maximum 
PET signal at 108 mm ± 2 mm, see figure 5(b) in Cho et al 2013b) to demonstrate that the 
implantation of markers does not have to occur in the exact depth of maximum activation. 
Details of the measurement setups are shown in table 5.1.  
The irradiated phantoms were then moved to an off-site PET/CT scanner (Discovery 
PET/computed tomography (CT) 690 scanner, GE Healthcare, Waukesha, WI) at the MD 
Anderson Center for Advanced Biomedical Imaging Research. The two phantoms (inferior 
and superior) were stacked, with the superior phantom on top of the inferior phantom, on the 
couch and simultaneously imaged for 5 hours. Multiple PET images were reconstructed with 
different PET scan times (20, 30, 40, 120 and 240 min), each with a 15 min incremental 
delay time (30, 45, 60 till 150 min) post proton irradiation. For example, the 20 min scan 
was acquired at 30, 45, 60, till 150 min post irradiation. The SNR of these images were then 
evaluated by 13 radiologists. 
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(a) 
 
 
(b) 
 
Figure 5.1 (a) Proton irradiation setup for Cu and 68Zn markers embedded in the superior 
balsa wood phantom. (b) Locations of markers overlaid on the percentage depth dose (PDD) 
curve of the proton beam. 
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Table 5.1 Proton irradiation and positron emission tomography (PET) scan setup for Cu and 68Zn markers embedded in low-density 
balsa wood (ρ ~ 0.1 g/cm3) phantoms. 
 
 
Group 1 experiments – Low-density balsa wood phantom irradiation 
Experiment 1 Experiment 2 Experiment 3 
Factor Sup phantom Inf phantom Sup phantom Inf phantom Sup phantom Inf phantom 
Dose, Gy 5.0 1.0 2.0 3.0 1.0 1.0 
Irradiation sequence 1st 2nd 2nd 1st Irradiated together 
Energy/Range/Mod/FS 160 MeV / 110 mm 90% Range / 10 cm Mod / 25 × 25 cm2 
Irradiation time, min 6.5 1.4 2.8 4.7 1.4 
Cu volume, mm3 ←          10, 20, 50          → 
68Zn volume, mm3 10, 20, 50 20 10, 20, 50 20 10, 20, 50 20 
Upstream water-equivalent 
thickness, mm 
106  106  108  108  108  104  
Water-equiv. depth of 68Zn 
locations/PDD 
108 mm/99% 108 mm/99% 110 mm/87% 110 mm/87% 110 mm/87% 106 mm/100% 
Water-equiv. depth of Cu 
locations /PDD 
107-113 mm/ 
99-29% 
107-113 mm/ 
99-29% 
109-115 mm/ 
95-6% 
109-115 mm/ 
95-6% 
109-115 mm/ 
95-6% 
105-111 mm/ 
100-71% 
Delay time, min ←          30, 45, 60, 75, 90, 105, 120, 135, 150          → 
PET scan time, min 20, 30, 40, 120 20, 30, 40, 120, 240 20, 30, 40, 120, 240 
Abbreviations: MOD, modulation wheel size; PDD, percentage depth dose. 
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5.2.3 Group 2 experiments – Beef phantom irradiation 
 
Two experiments were performed using beef phantoms. In both experiments (exp. 4 
and 5), two similar chunks of beef were purchased and served as superior and inferior 
phantoms (similar to the balsa wood phantom arrangement). Each phantom was sliced into 5 
layers (of approximately 14 × 12.5 × 0.5 cm) and stacked on top of one another in a 
cardboard box (14 × 12.5 × 4 cm) with a plastic wrap lining, for a final phantom size of 14 × 
12.5 × 2.5 cm. Depths 1 – 4 were defined similar to that of the balsa slabs. Each beef 
phantom was sealed inside a Ziploc bag (S. C. Johnson & Son, Racine, WI) to prevent any 
fluid leaks. Before CT scanning, multiple CT wires were placed between the cuts where 
markers were to be embedded to co-register the marker locations with respect to the isodose 
curves. Treatment planning was performed, and isodose curves were generated inside the 
phantoms in a manner similar to the balsa wood phantom (see previous section). 
After planning, the superior phantom was embedded with one 10 mm3 and one 20 
mm3 68Zn marker at depth 3; in addition, 10 mm3, 20 mm3, and 50 mm3 Cu markers were 
also imbedded at all depths (depths 1 – 4) in this phantom. The inferior phantom, on the 
other hand, was embedded with one 20 mm3 and one 50 mm3 68Zn marker at depth 3 and 10 
mm3, 20 mm3, and 50 mm3 Cu markers at al depths (depths 1 – 4).  
For experiment 4, proton doses of 5 and 2 Gy were delivered to the superior and 
inferior phantoms, respectively, with an upstream water-equivalent thickness of 90 mm. For 
experiment 5, the superior and inferior phantoms were irradiated with 3 and 1 Gy, 
respectively, with an upstream water-equivalent thickness of 85 mm. The two experiments 
were performed 24 hours apart to allow the activated samples to decay (11C T½= 20 min). 
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Between measurements, the beef phantoms were stored in a refrigerator to maintain their 
freshness. Details of the measurement setups are shown in table 5.2. 
After each experiment, the irradiated phantoms were moved to the same off-site 
PET/CT scanner and scanned in a similar manner to the balsa phantom.  
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Table 5.2 Proton irradiation and PET scan setup for Cu and 68Zn markers embedded in beef 
(round eye, USDA grade, ρ ~ 1.05 g/cm3) phantoms.  
 
Experiment 
Group 2 – Beef phantom irradiation 
 Experiment 4 Experiment 5 
Phantom Sup phantom Inf phantom Sup phantom Inf phantom 
Dose, Gy 5.0 2.0 3.0 1.0 
Irradiation sequence 1st 2nd 1st 2nd 
Energy/Range/Mod/FS 160 MeV / 110 mm 90% Range / 10 cm Mod wheel / 25 × 25 cm2 
Irradiation time, minutes 6.1 2.5 3.7 1.3 
Cu volume, mm3 ←          10, 25, 50          → 
68Zn volume, mm3 10, 20 20, 50 10, 20 20, 50 
Upstream water-equivalent 
thickness, mm 
←     90 mm     → ←     85 mm     → 
Water-equiv. depth of 68Zn 
locations, mm/PDD, % 
110mm/ 
87% 
110mm/ 
87% 
105mm/ 
100% 
105mm/ 
100% 
Water-equiv. depth of Cu 
locations, mm/PDD, % 
100-115mm/  
100-6% 
100-115mm/  
100-6% 
95-110mm/  
100-87% 
95-110mm/  
100-87% 
Delay time, minutes ←          30, 45, 60, 75, 90, 105, 120, 135, 150          → 
PET scan time, minutes 20, 30, 40, 120, 240 20, 30, 40, 120, 240 
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5.2.4 Image analysis 
 
PET images from different delay times were compared and only the image sets correspond 
to the highest marker SNR (from visual assessment) were selected for further analysis. The 
selected PET images (of different scan times and doses) and corresponding CT scan and 
fusion images were presented to 13 radiologists with expertise in nuclear medicine. Marker 
visibility was evaluated based on a 1 – 5 score with respect to the background (5 – strongly 
visible, 4 –moderate to strongly visible, 3 – moderately visible, 2 – weakly visible, and 1 – 
unsure/noise level/not visible). Since the superior phantom in experiment 1 was irradiated by 
the highest dose (5 Gy), the corresponding PET images from the 50 mm3 Cu markers when 
scanned for 30 min were used as a scoring reference with a score of 5. The visibility scores 
for the different combinations of marker volumes (10, 20, and 50 mm3) of Cu and 68Zn 
embedded in either balsa wood or beef phantoms and irradiated by different proton dose (1, 
2, 3, and 5 Gy) with reconstruction done using three different PET acquisition times (20, 30, 
and 40 min) were then reported. A visibility score of 3 (moderately visible) was chosen as 
acceptable and the corresponding volumes of markers were determined.  
 Analysis of variance (ANOVA) was used to assess the effect of the experimental 
factors on the image scores, whereby marker types (Cu or 68Zn), marker volume, dose, PET 
scan duration, and phantom materials (balsa or beef) were used as covariates. We also 
accounted for radiologist-specific random effects by taking into consideration the correlation 
of scores given by the same reader. A Tukey's honest significant difference (HSD) test was 
used to find means that are significantly different from each other. A linear model was 
developed, with marker visibility scores as response variable and the same set of covariates 
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as described just above, to understand how marker volume affects the visibility score. 
Specifically, we fit the linear model and used the parameter estimates to calculate the 
minimum marker volume that would yield an expected visibility score of 3 under the model 
assumptions.  
A verification study was performed using a determined Cu marker volume (which 
gives a visibility score of 3) in a beef phantom when irradiated by 5 Gy and PET scanned for 
30 min. This study was also done as a practical illustration how the proton range can be 
verified using implanted markers. 
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5.3 Results 
 
PET/CT fusion images of the superior phantom of experiment 1 in the balsa wood phantom 
irradiation (5 Gy) are shown in figure 5.2. The images were reconstructed with a 30-min 
PET scan following a 60-min delay (table 5.1). Figure 5.2(a) shows the beam’s eye view of 
the activated markers in plane for depth 3 (108 mm water-equivalent depth / 99% PDD). In 
this image, 50 mm3 Cu and 50 mm3 68Zn markers show moderate/strong and strong 
activations (visibility scores of 4 and 5, respectively), while the 20 mm3 Cu marker shows 
moderate activation (visibility score of 3). Both 10 mm3 and 20 mm3 68Zn markers show 
weak activations (visibility score of 2), while the 10 mm3 Cu marker does not show any 
noticeable activation (visibility score of 1). Figure 5.2(b) is a lateral view of the same 
phantom and shows activations of 50 mm3 Cu markers at all depths (107 – 113 mm / 99 – 
29 % PDD). At shallow depths, 50 mm3 Cu markers show strong signals, but as depth 
increases, the signals decrease. This image (figure 5.2(b)) was used as the reference image 
for the 13 radiologists to score the visibility of markers; a visibility score of 5 was assigned 
to the brightest markers (at depths 2 and 3), and a score of 1 was assigned to the darkest 
marker (depth 10). 
Although only selected/representative PET/CT fusion images are shown here, 
PET/CT fusion images for all doses, scan times, and phantom types were presented to the 13 
radiologists and an average visibility score was calculated for each marker in each case.  
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(a) 
 
(b)  
  
Figure 5.2 PET/CT fusion images of the superior phantom in experiment 1. (a) Beam’s eye 
view of the activated markers on the plane at depth 3 (108 mm/99%). (b) Lateral view on the 
plane of the 50 mm3 Cu markers.  
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Figure 5.3 shows PET/CT fusion images of the superior phantom from experiment 4 
in the beef phantom irradiation. The images were reconstructed with a 30-min PET scan 
following a 120-min delay (table 5.2). Figure 5.3(a) shows strong and weak signals from 50 
mm
3
 Cu and 20 mm3 Cu markers, respectively, when viewed from the beam’s eye view. 
Figure 5.3(b) shows strong signals from the same 50 mm3 Cu marker when viewed laterally. 
Although some signals shown in figure 5.3(a) are from markers placed on adjacent PET/CT 
slices, the beef generally had higher background signals than balsa wood.  
ANOVA analyses showed all main effects (marker type, marker volume, dose, PET 
scan time and phantom materials) and their first level interactions (for example, marker type 
and volume combined effect) were statistically significant (p-value < 0.001). Tukey’s HSD 
test showed all main effects changed the mean visibility scores significantly (p-value < 
0.001) except for changing PET scan time from 30 min to 40 min (p-value > 0.95) which did 
not impact the visibility scores significantly. 
Figure 5.4 shows the surface plot of average visibility scores of various volumes of 
Cu and 68Zn markers irradiated by different dose. Although individual variations and 
fluctuations exist, the general trend is that the visibility score increases as volume and dose 
increase. Increased PET acquisition time improves the visibility scores in general but more 
significantly at the high dose and marker volume region. Data from 68Zn markers embedded 
in the beef phantom are not shown here (see discussion).  
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(a) 
 
(b) 
 
Figure 5.3 Superior phantom of experiment 4. (a) Beam’s eye view on the plane at depth 2 
(105 mm/100%). (b) Lateral view on the plane of the 50 mm3 Cu marker. 
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Figure 5.4 Variation of average visibility scores with marker volume and dose for different 
marker materials, embedding phantom materials and PET scan times. The mesh grid is a 
linear interpolation of the measurement points (solid spheres). 
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Table 5.3 was obtained from the linear regression model constructed using the data 
presented in figure 5.4 and shows the required volume of markers to provide a visibility 
score 3 for each marker type – phantom material combination. As can be expected from the 
surface plot in figure 5.4, the required marker volume decreases with dose and PET scan 
time. Minimal difference is shown between different phantom materials, however, different 
marker types show a significant difference. Therefore, the phantom material difference was 
averaged and presented as a single marker volume table which can be used for both low 
density balsa wood and beef phantoms (table 5.4). 68Zn markers shows approximately 2 to 3 
times greater sensitivity compared to Cu markers. Both Cu and 68Zn markers showed the 
highest SNR when the post-irradiation delays were 60-min and 120-min, when markers were 
embedded in balsa wood and beef phantoms, respectively. 
Figure 5.5(a) shows results from the verification study. A volume of 25 mm3 Cu 
markers were used to validate the accuracy of a determined volume (26.7 mm3) in table 5.3. 
The top of figure 5.5(a) shows a PET/CT fusion image of the markers embedded in the beef 
phantom. The bottom of figure 5.5(a) shows isodose curves and marker locations overlaid 
on the same CT slice. Markers 1 and 2 show strong and marginal signals, respectively. 
Similarly, figure 5.5(b) shows images for 50 mm3 Cu markers. 10 mm3 Cu markers were 
irradiated similarly but did not show noticeable PET signals (results not shown here). Cu 
markers located at dose greater than the 95% isodose line showed sufficient PET visibilities 
while markers located at lower dose showed insufficient visibilities.  
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Table 5.3 The required volume of markers to provide a visibility score of 3. 
 
 Required marker volume (mm3) - Cu markers in low density 
balsa  
 Dose (Gy) 
PET scan time 
(min) 
1 2 3 4 5 
20 54.9 48.7 42.5 36.3 30.1 
30 51.8 45.6 39.4 33.2 27.1 
40 48.8 42.6 36.4 30.2 24.0 
 
 
 Required marker volume (mm3) - Cu markers in beef phantom  
 Dose (Gy) 
PET scan time 
(min) 
1 2 3 4 5 
20 54.6 48.4 42.2 36.0 29.8 
30 51.5 45.3 39.1 32.9 26.7 
40 48.5 42.3 36.1 29.9 23.7 
 
 
 Required marker volume (mm3) - 68Zn markers in low density 
balsa 
 Dose (Gy) 
PET scan time 
(min) 
1 2 3 4 5 
20 35.2 29.0 22.8 16.6 10.4 
30 32.1 25.9 19.7 13.5 7.4 
40 29.1 22.9 16.7 10.5 4.3 
 
 
 Required marker volume (mm3) - 68Zn markers in beef phantom  
 Dose (Gy) 
PET scan time 
(min) 
1 2 3 4 5 
20 34.9 28.7 22.5 16.3 10.1 
30 31.8 25.6 19.4 13.2 7.0 
40 28.8 22.6 16.4 10.2 4.0 
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Table 5.4 The averaged required volume of markers of low density balsa wood and beef 
phantoms to provide a visibility score of 3. 
 
 Averaged required marker volume (mm3) - Cu markers 
 Dose (Gy) 
PET scan time 
(min) 
1 2 3 4 5 
20 55 49 42 36 30 
30 52 45 39 33 27 
40 49 42 36 30 24 
 
 
 Averaged required marker volume (mm3) - 68Zn markers 
 Dose (Gy) 
PET scan time 
(min) 
1 2 3 4 5 
20 35 29 23 16 10 
30 32 26 20 13 7 
40 29 23 17 10 4 
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(a) 
 
(b) 
Figure 5.5 Verification experiment using Cu markers imbedded in a beef phantom. In each 
image, top is PET/CT fusion images and bottom is isodose curves overlaid on CT of the 
same slide. Marker locations are shown for correlation. (a) 25 mm3 Cu markers. (b) 50 mm3 
Cu markers. 
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5.4 Discussions 
 
In this research we evaluated PET images of two tissue-like phantoms (low-density balsa 
wood and beef); the phantoms were embedded with different volumes (10, 20, and 50 mm3) 
of 68Zn and Cu markers, which were then irradiated with different doses (1, 2, 3, and 5 Gy) 
of protons, and then PET scanned over varying acquisition times (20, 30, and 40 min). As 
expected, we found that the visibility of activated markers increased proportionally to the 
marker volume, dose, and PET scan time. We also determined the volumes of markers that 
give acceptable visibility for different doses and scan times.  
Table 5.4 provides a lookup table to determine the volume of the marker appropriate 
for implantation. Once the clinic decides on the dose and PET scan time for the particular 
proton treatment and verification procedure, the marker volume that will give a visibility 
score of 3 can be selected. Since this table was derived using the currently available PET/CT 
scanners, with 0.95% sensitivity, the required marker volume may be increased or reduced 
by determining the ratio of the scanners sensitivities. Ideally, one type (and volume) of 
markers should be designed that guarantee acceptable PET visibility over the wide range of 
dose. 
The idea of implanting a dosimeter for proton range verification has been suggested 
by several investigators. Lu (2008a) and Gottschalk et al (2011) suggested the use of a small 
ion chamber or semiconductor diode for time-resolved proton range verification. However, 
currently no implantable detectors exist for this purpose. Alternatively, Lu (2008b) 
suggested that the proton path length be verified by measuring a ratio of two doses, each of 
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which is obtained by dividing the currently available passive flat SOBP profile into two 
oppositely sloped depth dose profiles.  
Our proposed approach has several advantages over Lu’s method. First, our marker 
system is more compact. In this research, marker volumes from 24 to 54 mm3 for Cu (4 to 
35 mm3 for 68Zn) were required to provide adequate PET signals after exposure of 1 to 5 Gy 
followed by a PET scan of 30 min. The required volume is comparable to non-gold fiducial 
markers (~ 10 mm3) at high dose region. Therefore, use of our markers for hypofractionated 
treatments such as stereotactic body radiation therapy (SBRT) and stereotactic ablative 
radiotherapy (SABR) might be more practical. In addition to that, the required volume of 
markers can be reduced with high sensitivity PET scanners. The sensitivity of the PET 
system used in this work is 0.95% which limited the visibility of the activated markers. Our 
results show that 10 mm3 68Zn markers irradiated by 1 Gy scored a visibility of 1 when 
scanned for 30 min but scored a visibility of 3 (results not shown) when scanned for 240 min 
(equivalent to 3 times increase in contrast difference between the activated 68Zn markers and 
the background). We note that brain PET scanners have higher sensitivities due to their 
smaller bore sizes.  
The second advantage of our approach over Lu’s method is that it does not require 
modified proton modulation, to divide the SOBP into two oppositely sloped profiles. We 
showed previously (figure 5.5(b) in Cho et al 2013b) that Cu’s activity profile is not flat at 
the SOBP region but instead gradually decreases towards the distal fall-off region. 68Zn’s 
activity profile increases gradually from the SOBP region and shows a broad peak at the 
start of the dose fall-off region. These gradual changes (or broad peak) are at least twice 
wider than the dose fall-off region, therefore placing markers in this region is not as 
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stringent as placing a dosimeter at the dose fall-off region. We also previously learned that 
activated Cu markers decay with different half-lives depending on the implantation location 
because Cu creates multiple progeny radioisotopes, each of which is created over a different 
energy range. This characteristic can be taken advantage of for proton range verification by 
measuring marker signal time activity curve. In this way, marker implantation location 
requirement becomes even more relaxed (markers can be even implanted at the SOBP 
region); however, detector sensitivity remains a large obstacle for this approach. 
There are some uncertainties and limitations in this research. Data from 68Zn markers 
embedded in the beef phantom had missing data points due to the limited availability of 68Zn 
markers and also provided unexpectedly low and irregular visibility scores, therefore were 
not included in the calculation of optimal marker volumes. The reason of unexpectedly low 
signals could be due to the change of depth of 68Zn markers in the phantom. Between CT 
scanning and treatment, deformation of beef phantoms occurred which caused the depth 
change. While Cu markers were embedded in 4 continuous depths therefore less influenced 
by this depth change, 68Zn markers were embedded in only 1 depth due to the limited 
number of markers. Therefore, data from 68Zn markers embedded in the beef phantom are 
not shown in figure 5.4 and also were not used in the linear regression model that was used 
to obtain tables 5.3 and 5.4. Another limitation of this study is the shape of the embedded 
markers. Only rectangular markers shapes of 10 × 10 mm (0.1 – 0.5 mm in thickness) were 
used. In fact, this rectangular marker shape cannot possibly be a practical patient 
implantable marker shape. Investigation for optimal marker designs/shapes will be the 
subject of future research. 
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Our approach also carries an inherent disadvantage of added PET scan time after a 
proton treatment. It will be impractical to perform PET after each treatment; instead, patients 
may benefit from a weekly or bimonthly scan, assuming that the proton path length does not 
change significantly day to day. Additionally, our approach is invasive and limited to point 
proton range verifications. Several markers have to be implanted for proton range 
verification if critical organs are relatively large and a drastic change of tissue heterogeneity 
is expected along the direction perpendicular to the beam.  
Figure 5.5 shows a practical application of implanted markers for proton range 
verification. 25 mm3 Cu markers were used since it was close enough to the required volume 
– 26.74 mm3. 10 mm3 and 50 mm3 Cu markers provided minimal and stronger PET signals, 
respectively which show that the estimated volume of Cu marker – 26.74 mm3 was adequate. 
By correlating marker activation with isodose curves, proton range verification can be 
achieved. Although our previously results (Cho et al 2013b) showed Cu demonstrated 
sufficient activation as low as 50% isodose region, figure 5.5 shows Cu marker activation 
only at > 95% isodose region. This finding seems contradictory to the previous results; 
however, we believe the difference is due to the different delay times used for the PET scans 
(50 min in the previous studies, but 2 hours here). As already explained in figure 5.6, natural 
copper has multiple nuclear interaction schemes whose progeny radioisotopes decay with 
different half-lives. Among these many interactions, the 63Cu(p,n)63Zn interaction occurs 
most abundantly at the low proton energy (distal fall-off) region, and its progeny 63Zn 
decays with a half-life of 38.47 min. Therefore, while signals were observed at the 50% 
isodose region when the delay was only 50 min, they were not observed when the delay was 
longer.   
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Figure 5.6 Proton nuclear interaction cross-sections of natural copper. B+ stands for the 
branching ratio of positron emissions to the total (positron emissions + electron capture). 
Source: http://www.nndc.bnl.gov/exfor/exfor00.htm.  
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Two patient groups are expected to benefit the most from the developed proton 
activated markers – thoracic/liver SBRT/SABR and head/neck patients. Due to the nature of 
delivering higher dose under a limited immobilization, thoracic/liver SBRT/SABR patients 
are exposed to a greater risk of over/under-irradiation. Especially the lung suffers from 
relatively large proton range uncertainties due to low density. Also, tumors in the head & 
neck region are often surrounded by critical organs. By implanting markers at the interface 
between the target and critical organs, several improvements can be made in the treatment 
plan while sparing the critical organs. This includes the margin reduction and the flexibility 
in beam angle choices. 
We envision that the clinical application of proton activated markers can be as 
follows. A tandem of 3 markers can be connected with spacers in between. This tandem 
markers can be implanted diagonally to the proton beam direction (to avoid markers beam 
shadowing each other) at the interface between the tumor and the critical organs. The 
implantation location can be carefully chosen from a treatment plan so that two proximal 
markers are activated and one distal marker is not activated if the actual treatment was 
executed as treatment planned. If the range of protons that the patient received was longer 
than what was planned, all three markers will be activated. Similarly, if the range of protons 
was shorter than what was planned, only one proximal marker will be activated. The 
distance of spacers in the tandem markers can be controlled in accordance with the desired 
accuracy of proton range estimation. Before first proton treatments, these tandem markers 
can be implanted in patients and the proton ranges for subsequent treatments can be adjusted 
according to the proton ranges determined by marker measurements.  
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In this research, we characterized different PET/CT fusion images and determined 
the required volumes of implantable proton-activated markers with examples of Cu and 68Zn 
markers embedded in tissue-like phantoms using clinically feasible dose and PET scan time 
ranges. Optimal post-irradiation times were also determined for different phantom materials. 
The marker volumes provided can be used as a guideline in designing practical implantable 
markers. Future studies will focus on designing markers, planning preclinical studies using 
anthropomorphic phantoms or animals, with a long-term goal of optimizing such markers 
for clinical use. These studies will be performed using an actual patient treatment and 
verification scenario.  
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Chapter 6 
Discussion and Future Work 
__________________________________________________________________________ 
 
 
 
Positron emission tomography (PET) has been suggested as an imaging technique for in vivo 
proton dose and range verification after proton induced-tissue activation. During proton 
treatment, irradiated tissue is activated and decays while emitting positrons. In chapter 3, we 
assessed the feasibility of using PET imaging after proton treatment to determine tissue 
elemental composition by evaluating the resultant composite decay curve of activated tissue.  
For the Specific Aim I (chapter 3), we obtained oxygen and carbon composition 
information from proton irradiated phantoms as well as two proton therapy patients using an 
in-room PET. Excellent agreement (within 4%) between the estimated carbon/oxygen 
percentage and the actual percentage was obtained in the irradiated phantoms. Moderate 
agreement (within 15%) was obtained in the same estimation for irradiated patients. These 
uncertainties are largely attributed to perfusion driven activity washout. After patient 
irradiation, the decrease in PET signals over time occurs not only due to radioisotope decays 
(physical decay) but also due to activity washout mostly from blood flow (biological decay). 
Those biological decays are corrected by organ dependent washout models, however, the 
currently available models do not account for the washout heterogeneity inside the same 
organ as well as the differences in different radioisotopes. The uncertainties of the currently 
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available washout models have a direct impact in the accuracy of the presented elemental 
tissue decomposition method which is a major limitation of the research.  
Despite this limitation, tissue elemental composition information obtained with 
moderate uncertainties can improve stopping power calculation which is a backbone of 
proton dose and range calculation using treatment planning system. Additionally, the 
obtained tissue elemental composition information is expected to improve proton therapy 
verification using PET. Currently dose verification using PET is possible only for 
homogeneous media but providing tissue elemental composition is one step forward towards 
the clinical realization of dose verification using PET. Although the added elemental tissue 
composition information is expected to improve stopping power calculation as well as 
possibly dose verification in the future, the relatively low sensitivity of the mobile PET 
scanner (NeuroPET, Photo Diagnostic Systems, Boxboro, MA) used in this research was a 
limiting factor in providing accurate tissue elemental composition information. However, 
recently a newer version of mobile PET/CT scanner (NeuroPET/CT, Photo Diagnostic 
Systems, Boxboro, MA) was installed at Massachusetts General Hospital with sensitivity 
approximately 3 times greater than the older mobile PET (personal communication, CH 
Min). This new system also has an integrated CT capability which will significantly reduce 
PET and CT image coregistration errors. This newer scanner is expected to provide more 
accurate tissue elemental composition which even may enable the detection of treatment 
responses such as necrosis. 
 The use of this newer scanner may even allow an alternative method of proton range 
detection immediately after treatment. 16O(p,α)13N interaction cross-section shows a peak at 
low energy protons which are abundant near the distal end of proton range (figure 3.2). 
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According to the analysis of in-room PET data used for chapter 3 of this research but whose 
results were not presented in this dissertation, a sudden increase of 13N signals (a component 
with a half-life of 10 min when time-activity curves were separated using least-squares 
methods) was common near the distal end of the proton range. However, due to low detector 
sensitivity a relatively large PET voxel is required to observe a peak of 13N signals which 
hinders a precise detection of the distal end location. The higher sensitivity of a newer 
NeuroPET/CT scanner may provide consistently high 13N signals in small voxels which can 
be correlated with the distal end of the proton range. 
 I find it worth it mention that initially we tried to perform the Specific Aim I using 
an off-site full body PET scanner near MD Anderson Cancer Center Proton Therapy Center 
with a minimum post-irradiation delay of 15 min which was not possible due to no/weak 
signals from 10C/15O progeny radioisotopes which were essential for this approach. An on-
site full body PET scanner with a minimum post-irradiation delay can be utilized in the 
future research to examine other body sites for elemental tissue composition imaging or 
treatment response imaging. 
 For the Specific Aim II and Specific Aim III of this dissertation, we studied 
feasibility (chapters 4) and characterization (chapter 5) of patient implantable proton 
activated fiducial markers using an off-site PET. Proton beam range verification using 
positron emission tomography (PET) currently relies on proton activation of tissue, the 
products of which decay with a short half-life and necessitate an on-site, in-room or in-beam 
PET scanner. This method is not feasible for many proton therapy centers due to high cost of 
those PET scanner. Additionally, tissue activation is negligible near the distal dose fall-off 
region of the proton beam range due to their high interaction energy thresholds. Therefore 
  
95 
 
Monte Carlo simulation is often supplemented for comparison with measurement; however, 
this also may be associated with systematic and statistical uncertainties. Therefore, in 
chapter 4 we sought to test the feasibility of using long-lived proton-activated external 
materials that are inserted or infused into the target volume for more accurate proton beam 
range verification that could be performed at an off-site PET scanner.  
 Three candidate materials (18O, Cu and 68Zn) were studies and all of them showed 
strong activation near the proton distal fall-off region. The depth activity profiles of all three 
candidate materials mimicked the dose fall-off closely with an off-set of 1 to 2 mm. 
Additionally, the radioisotopes created from the proton activation of candidate materials 
decay with relatively long half-lives. Therefore, widely available off-site PET scanners can 
be utilized to estimate the proton range from activation of those candidate materials. 
Irradiation of phantoms embedded with markers made of those candidate materials show 
strong PET signals which show much potential as proton range verification markers. 
Also, the characterization studies (chapter 5) determined the optimal volumes of Cu 
and 68Zn markers which give acceptable PET signals for different dose, PET scan time and 
imbedded in two tissue-like phantom materials. For both phantoms, the visibility of 
activated markers increased in proportion to the marker volume, dose, and PET scan time as 
expected. However, no clear relationship was found for different phantom materials. Tables 
for marker PET signal strength/visibility for different volumes, phantom materials, doses, 
and scan time were generated. From these tables, volumes of markers which provide 
adequate visibility were suggested for each dose and PET scan time. Using a suggested 
volume of markers, a verification experiment was performed as pseudo clinical studies 
simulating proton range verification in the lung and soft-tissue. Treatment plan created 
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isodose curves were correlated with marker PET signals to predict the proton range. The 
information provided can be used as a guideline in designing implantable fiducial makers, 
planning preclinical studies using anthropomorphic phantoms or animals, with a long-term 
goal of optimizing such markers for clinical use.  
Although the method seems very promising, several steps of pre-clinical research are 
necessary to make clinical implementation possible. Two pre-clinical researches are 
suggested here. First, a mock patient treatment can be performed using an anthropomorphic 
phantom embedded with proton activated markers such as 68Zn and Cu along with 
dosimeters such as TLD (Thermo Luminescence dosimeter) or OSLD (Optically Stimulated 
Luminescence Dosimeter). After CT scanning this phantom, treatment planning can be 
performed using a realistic patient treatment protocol. Treatment beams can be arranged so 
that information obtained from embedded markers and dosimeters can provide the proton 
range. After irradiation of proton beams, the phantom can be moved to an off-site PET 
scanner and imaged for signals from embedded markers. After PET scan, the dosimeters can 
be removed for dose measurement whose results can be used as a gold standard in 
estimating proton range. Heterogeneity such as lung or bone equivalent materials can be 
introduced in the anthropomorphic phantom to test the accuracy of this proton range 
verification method compared with the estimation obtained from the treatment planning.  
 Second, a pre-clinical study can be performed using a human-sized animal such as a 
pig by implanting proton activated markers followed by similar steps described above for 
the anthropomorphic phantom study. Since it is very difficult to implant metal foils (which 
were used in this research) inside the animal, it is necessary to perform a sensitivity study of 
markers whose shape (such as cylinder or wire) is easier to implant. Although, it was not 
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presented in this dissertation, measurements were performed to test the sensitivity (PET 
signal strength) of Cu wires with various diameters (0.3 – 1 mm) irradiated by protons near 
the end of the range. Although, the PET signal increased with diameter (given that all wires 
are the same length), the signal per wire volume increased rapidly as the diameter decreases. 
Similarly, 2 mm diameter Cu balls and Cu cylinders were proton irradiated and resulted in 
significantly less PET signals per volume compared to thin Cu wires. This can be explained 
from the fact that the wires with smaller diameters are activated almost entirely while the 
wires with larger diameters and Cu balls/cylinders are only activated at the surface because 
the protons slow down rapidly and stop while passing through the metal. Therefore, it is 
beneficial to implant thinner markers to obtain a high signal to marker volume ratio.  
A commercial fiducial marker called VISICOILTM (IBA Dosimetry GmbH 
Bahnhofstrasse 5, 90592 Schwarzenbruck, Germany) provide some insight for the future 
marker design. Although it is made of very thin gold wires (0.1 ~ 0.2 mm diameter), when 
coiled it provides adequate radiographic opacity for CT or radiographic x-ray. The future 
proton activated markers can be designed similarly into coils to provide maximum PET 
signal sensitivity per marker volume. Another commercial fiducial marker called Gold 
AnchorTM (The fine needle marker, Nasland Medical AB, Vassvägen 21, 14139 Huddinge, 
Sweden) has a shape of very thin (~ 0.2 mm) and long notched gold wires which can be 
implanted using very fine needles such as 22 gauge (0.71 mm diameter) or 25 gauge (0.53 
mm diameter) needles. Once these long notched gold wires are inserted, they can be 
collapsed to form a near cylindrical shape which shows the maximum radiographic opacity. 
Compared to the conventional fiducial markers which require 17 gauge (1.47 mm diameter) 
or 18 gauge (1.27 mm) needles, this method has the reduced risks of pneumothorax, 
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infection, bleeding, and seeding of cancer cells by using smaller diameter needles. A similar 
method can be taken advantage of to implant proton activated fiducial markers such as by 
programming the wire to collapse into a certain shape to provide the maximum PET signal 
sensitivity per volume. 
Currently proton treatment is restricted with respect to adjacent critical organs. By 
implanting markers at the interface between the target and critical organs, margin reduction 
can be achieved. Hypo-fractionation and stereotactic ablative radiotherapy can be practiced 
with the assurance of critical organ sparing. The two patient groups are expected to benefit 
the most from the developed proton activated markers – thoracic/liver SBRT and 
CNS/head/neck patients. Due to the nature of delivering higher dose under a limited 
immobilization, thoracic/liver SBRT patients are exposed to a greater risk of over/under-
irradiation. Especially the lung suffers from relatively large proton range uncertainties due to 
low density. Tumors in the CNS/head/neck region are often surrounded by critical organs. 
Accurate proton range verification using implanted markers can provide more flexibility in 
treatment techniques such as the selection of beam angles, therefore, minimize the risk of 
damaging surrounding critical organs. Successfully developed markers in the future studies 
will be tested using anthropomorphic phantoms representing various clinical sites. Dose 
used throughout this research is Co-60 equivalent dose in Gy not in biologically equivalent 
dose (RBE).  
In this dissertation, we utilized both in-room and off-site PETs to determine both 
phantom and patient elemental composition and to determine the proton range by utilizing 
novel proton activated isotopes. The proposed elemental composition acquisition technique 
can be used to improve the proton dose and range calculation as well as proton dose 
  
99 
 
verification using PET. The proposed proton activated implantable marker technique 
introduces a novel method of proton range verification. All specific aims have been 
accomplished throughout this research and this concludes the dissertation. 
  
  
100 
 
References 
__________________________________________________________________________ 
 
 
 
Alpen EL, Saunders W, Chatterjee A, Llacer J, Chen GTY and Scherer J 1985 A 
comparison of water equivalent thickness measurements: CT method vs. heavy ion beam 
technique Br. J. Radiol. 58 542–8 
 
Arce P, Rato P, Canadas M and Lagares JI 2008 GAMOS: a GEANT4-based easy and 
flexible framework for nuclear medicine applications IEEE NSS/MIC Conf. Prcd. 3162–
3168 
 
Bichsel H 1972 Passage of charged particles through matter American Institute of Physics 
Handbook (New York:McGraw-Hill) pp 8-142–89 
 
Blomlie V, Rofstad E K, Skjønsberg A, Tverå K and Lien H H 1995 Female pelvic bone 
marrow: serial MR imaging before, during, and after radiation therapy Radiology 199 537–
43 
 
Brewer GJ 2010 Copper toxicity in the general population. Clin Neurophysiol. 2010 
Apr;121(4):459–60. 
 
  
101 
 
Cheung J, Kudchadker R, Zhu R, Lee A and Newhauser W 2010 Dose perturbations and 
image artifacts caused by carbon-coated ceramic and stainless steel fiducials used in proton 
therapy for prostate cancer Phys. Med. Biol. 55 7135–47 
 
Cho J, Schulte R and Patyal B 2009 A feasibility study of using O‐18 enriched water to 
develop a method of in‐vivo range verification in proton therapy Med. Phys. 36, 2509 
 
Cho J, Mawlawi O, Gillin M, Titt U, Gonzalez‐Lepera C and Ibbott G 2011 Proton beam 
range verification with PET: comparison of O‐18, O‐16 and C‐12 activation Med. Phys. 38, 
3831 
 
Cho J, Ibbott G, Gillin M, Gonzalez-Lepera C, Min C H, Zhu X, El Fakhri G, Paganetti H 
and Mawlawi O 2013a Determination of elemental tissue composition following proton 
treatment using positron emission tomography Phys. Med. Biol. 58 3815–35 
 
Cho J, Ibbott G, Gillin M, Gonzalez-Lepera C, Titt U, Paganetti H, Kerr M and Mawlawi O 
2013b Feasibility of proton-activated implantable markers for proton range verification 
using PET Phys. Med. Biol. 58 7497–7512 
 
Cookson J A 1974 Radiography with protons Naturwissenschaften 61 184–91 
 
Cormack A M and Koehler A M 1976 Quantitative proton tomography Phys. Med. Biol. 21 
560–69 
  
102 
 
 
Crespo P, Shakirin G and Enghardt W 2006 On the detector arrangement for in-beam PET 
for hadron therapy monitoring Phys. Med. Biol. 51 2143–63 
 
EnghardtW, Parodi K, Crespo P, Fiedler F, Pawelke J and Poenisch F 2004 Dose 
quantification from in-beam positron emission tomography Radiother. Oncol. 73 (Suppl. 2) 
96–98 
 
España S and Paganetti H 2010 The impact of uncertainties in the CT conversion 
algorithmwhen predicting proton beam ranges in patients from dose and PET-activity 
distributions Phys. Med. Biol. 55 7557–71 
 
España S, Zhu X, Daartz J, El Fakhri G, Bortfeld T and Paganetti H 2011 The reliability of 
proton-nuclear interaction cross-section data to predict proton-induced PET images in 
proton therapy Phys. Med. Biol. 56 2687–98 
 
Experimental Nuclear Reaction Data (EXFOR), National Nuclear Data Center, Brookhaven 
National Laboratory, http://www.nndc.bnl.gov/exfor/exfor00.htm, Accessed July 2012 – 
May, 2013 
 
Fiedler F, Shakirin G, Skowron J, Braess H, Crespo P, Kunath D, Pawelke J, P¨onisch F and 
EnghardtW 2010 On the effectiveness of ion range determination from in-beam PET data 
Phys. Med. Biol. 55 1989–98 
  
103 
 
 
Gensheimer M F Yock T I, Liebsch N J, Sharp G C, Paganetti H, Madan N, Grant P E and 
Bortfeld T 2010 In vivo proton beam range verification using spine MRI changes Int. J. 
Radiat. Oncol. Biol. Phys. 78 268–75 
 
Gottschalk B, Tang S, Bentefour E H, Cascio E W, Prieels D and Lu H M 2011 Water 
equivalent path length measurement in proton radiotherapy using time resolved diode 
dosimetry Med. Phys. 38 2082–88 
 
Graffman S and Jung B 1975 11C and 15O induced in the mouse by 175 MeV protons Acta 
Radiologica Vol.14 Fasc.2 April 1975 
 
Hanson K M, Bradbury J N, Koeppe R A, MacEk R J, MacHen D R, Morgado R, Paciotti M 
A, Sandford S A and Steward V W 1982 Proton computed tomography of human specimens 
Phys. Med. Biol. 27 25–36 
 
Huang S C, Carson R E, Hoffman E J, Kuhl D E and Phelps M E 1982 An investigation of a 
double-tracer technique for positron computerized tomography Journal of nuclear medicine 
: official publication, Society of Nuclear Medicine 23 816–22 
 
Huang J, Newhauser W, Zhu R, Lee A, Kudchadker R 2011 Investigation of dose 
perturbations and the radiographic visibility of potential fiducials for proton radiation 
therapy of the prostate Phys. Med. Biol. 56 5287–302 
  
104 
 
 
Hughes W L, Nussbaum G H, Connolly R, Emami B and Reilly P 1979 Tissue perfusion 
rate determined from the decay of oxygen-15 activity after photon activation in situ Science 
204 1215–7 
 
ICRU 1992 Photon, electron, proton and neutron interaction data for body tissues ICRU 
Report no 46 (Bethesda, MD: ICRU) 
 
Iljinov A S, Semenov V G, Semenova M P, Sobolevsky N M and Udovenko L V 1994 
Production of radionuclides at intermediate energies. subvol. I/13d, Interactions of protons 
with nuclei (Supplement to I/13a,b,c). Ed. Schopper H, Landolt-Boernstein, New Series, 
Springer-Verlag. 
 
Jiang H and Paganetti H 2004 Adaptation of GEANT4 to Monte Carlo dose calculations 
based on CT data Med.Phys. 31 2811–8 
 
Jiang J, Seco J and Paganetti H 2007 Effects of Hounsfield number conversion on CT based 
proton Monte Carlo dose calculations Med. Phys. 34 (4) 1439–49 
 
Knopf A, Parodi K, Paganetti H, Cascio E, Bonab A and Bortfeld T 2008 Quantitative 
assessment of the physical potential of proton beam range verification with PET/CT Phys. 
Med. Biol. 53 4137–51 
 
  
105 
 
Knopf A, Parodi K, Bortfeld T and Paganetti H 2009 Systematic analysis of biological and 
physical limitations of proton beam range verification with offline PET/CT scans Phys. 
Med. Biol. 54 4477–95 
 
Knopf A, Parodi K, Paganetti H, Bortfeld T, Daartz J, Engelsman M, Liebsch N and Shih H 
2011 Accuracy of proton beam range verification using post-treatment positron emission 
tomography/computed tomography as function of treatment site Int. J. Radiat. Oncol. Biol. 
Phys. 79 297–304 
 
Koehler A M 1968 Proton Radiograpy Science 160 303 
 
Kramer S L et al 1977 Application of proton radiography to medical imaging Proc. 1st Int. 
Seminar on the Use of Proton Beams in Radiation Therapy, (Moscow, Russia) 
 
Litzenberg D W, Roberts D A, Lee M Y, Pham K, Vander Molen A M, Ronningen R and 
Becchetti FD 1999 On-line monitoring of radiotherapy beams: experimental results with 
proton beams Med. Phys. 26 992–1006 
 
Lomax A J, Boehringer T, Coray A, Egger E, Goitein G, Grossmann M, Juelke P, Lin S, 
Pedroni E, Rohrer B, Roser W, Rossi B, Siegenthaler B, Stadelmann O, Stauble H, Vetter C 
and Wisser L 2001 Intensity modulated proton therapy: a clinical example Med. Phys. 28 
317–24 
 
  
106 
 
Lu H M 2008a A potential method for in vivo range verification in proton therapy treatment 
Phys. Med. Biol. 53 1414–24 
 
Lu H M 2008b A point dose method for in vivo range verification in proton therapy Phys. 
Med. Biol. 53 N415–22 
 
Lu H M, Mann G and Cascio E 2010 Investigation of an implantable dosimeter for single-
point water equivalent path length verification in proton therapy Med. Phys. 37 5858–66 
 
Matsufuji N, Tomura H, Futami Y, Yamashita H, Higashi A, Minohara S, Endo M and 
Kanai T 1998 Relationship between CT number and electron density, scatter angle and 
nuclear reaction for hadron-therapy treatment planning Phys. Med. Biol. 43 3261–75 
 
Min C H, Kim C H, Youn M and Kim J 2006 Prompt gamma measurements for locating the 
dose fall-off region in the proton therapy Appl. Phys. Lett. 89 183517 
 
Min C H, Zhu X, Winey B A, Grogg K, Testa M, El Fakhri G, Bortfeld T R, Paganetti H 
and Shih H A 2013 Clinical application of in-room positron emission tomography for in 
vivo treatment monitoring in proton radiation therapy Int. J. Radiat. Oncol. Biol. Phys. 86 
183–9 
 
  
107 
 
Miyatake A, Nishio T, Tachikawa T and Yamada M 2009 Simulation system of positron 
emitter nuclei distribution in a patient body using target elemental activity pencil beam 
algorithm in proton therapy PTCOG 48th Meet. 28.09.–01.10.2009 
 
Miyatake A, Nishio T and Ogino T 2011 Development of activity pencil beam algorithm 
using measured distribution data of positron emitter nuclei generated by proton irradiation of 
targets containing C-12, O-16, and Ca-40 nuclei in preparation of clinical application Med. 
Phys. 38 5818–29 
 
Mizuno H, Tomitani T, Kanazawa M, Kitagawa A, Pawelke J, Iseki Y, Urakabe E, Suda M, 
Kawano A, Iritani R, Matsushita S, Inaniwa T, Nishio T, Furukawa S, Ando K, Nakamura Y 
K, Kanai T and Ishii K 2003 Washout measurement of radioisotope implanted by 
radioactive beams in the rabbit Phys.Med. Biol. 48 2269–81 
 
Moffett D R, Colton E P, Concaildi G A, Hoffman E W, Klem R D, Knott M J, Kramer S L, 
Martin R L, Parker E F, Passi A R, Schultz P F, Stockley R L, Timm R E, Skaggs L S and 
Steward V W 1975 Initial test of a proton radiographic system IEEE Trans. Nucl. Sci. 22 
1749–51 
 
Moyers MF, Sardesai M, Sun S and Miller D 2010 Ion stopping powers and CT numbers 
Med. Dosim. 35 179–94 
 
  
108 
 
Mustafa AA and Jackson DF 1983 The relation between x-ray CT numbers and charged 
particle stopping powers and its significance for radiotherapy treatment planning Phys. Med. 
Biol. 28 169–76 
 
Nishio T, Sato T, Kitamura H, Murakami K and Ogino T 2005 Distributions of β+ decayed 
nuclei generated in the CH2 and H2O targets by the target nuclear fragment reaction using 
therapeutic MONO and SOBP proton beam Med. Phys. 32 1070–82 
 
Nishio T, Miyatake A, Inoue K, Gomi-Miyagishi T, Kohno R, Kameoka S, Nakagowa K 
and Ogino T 2008 Experimental verification of proton beam monitoring in a human body by 
use of activity image of positron-emitting nuclei generated by nuclear fragmentation 
reaction Radiol. Phys. Technol. 1(1) 44–54 
 
Nussbaum G H, Purdy J A, Granda C O, Emami B and Sapareto S A 1983 Use of the 
Clinac-35 for tissue activation in noninvasive measurement of capillary blood flow Medical 
physics 10 487–90 
 
Oelfke U, Lam G K Y and Atkins M S 1996 Proton dose monitoring with PET: quantitative 
studies in Lucite Phys. Med. Biol. 41 177–96 
 
Paans A M J and Schippers J M 1993 Proton therapy in combination with PET as monitor: a 
feasibility study IEEE Trans. Nucl. Sci. 40 1041–4 
 
  
109 
 
Paganetti H, Jiang H, Parodi K, Slopsema R and Engelsman M 2008 Clinical 
implementation of full Monte Carlo dose calculation in proton beam therapy Phys. Med. 
Biol. 53 4825–53 
 
Paganetti 2012a Proton Therapy Physics CRC Press Taylor & Francis Group 6000 Broken 
Sound Parkway NW, Suite 300 Boca Raton, FL 33487–2742 
 
Paganetti 2012b Range uncertainties in proton therapy and the role of Monte Carlo 
simulations Phys. Med. Biol. 57 R99–R117 
 
Parodi K, Paganetti H, Cascio E, Flanz J B, Bonab A A, Alpert N M, Lohmann K and 
Bortfeld T 2007a PET/CT imaging for treatment verification after proton therapy: a study 
with plastic phantoms and metallic implants Med. Phys. 34 419–35 
 
Parodi K, Paganetti H, Shih H, Michaud S, Loeffler J, Delaney T, Liebsch N, Munzenrider 
J, Fischman A, Knopf A and Bortfeld T 2007b Patient study of in vivo verification of beam 
delivery and range, using positron emission tomography and computed tomography imaging 
after proton therapy Int. J. Radiat. Oncol. Biol. Phys. 68 920–34 
 
Parodi K, Bortfeld T and Haberer T 2008 Comparison between in-beam and offline positron 
emission tomography imaging of proton and carbon ion therapeutic irradiation at 
synchrotron- and cyclotron-based facilities Int. J. Radiat. Oncol. Biol. Phys. 71 945–56 
 
  
110 
 
Penfold S N, Rosenfeld A B, Schulte R W and Schubert K E 2009 A more accurate 
reconstruction system matrix for quantitative proton computed tomography Med. Phys. 36 
4511–48 
 
Polf J C, Peterson S, McCleskey M, Roeder B T, Spiridon A, Beddar S and Trache L 
 2009 Measurement and calculation of characteristic prompt gamma ray spectra emitted 
during proton irradiation Phys. Med. Biol. 54 519–27 
 
Priegnitz M, Fiedler F, Kunath D, Laube K, Parodi K, Sommerer F and Enghardt W 2008 A 
novel approach for predicting the positron emitter distributions produced during therapeutic 
ion irradiation IEEE Nucl. Sci. Sym. Conf. Rcd. 4516–9 
 
Priegnitz M, Fiedler F, Kunath D, Laube K and Enghardt W 2012 An experiment-based 
approach for predicting positron emitter distributions produced during therapeutic ion 
irradiation IEEE Trans. Nucl. Sci. 59 77–87 
 
Ramaseshan R, Kohli K, Cao F and Heaton R K 2008 Dosimetric evaluation of plastic water 
diagnostic-therapy J. Appl. Clin. Med. Phys. 9 98–111 
 
Remmele S, Hesser J, Paganetti H and Bortfeld T 2011 A deconvolution approach for PET-
based dose reconstruction in proton radiotherapy Phys. Med. Biol. 56 7601–19 
 
  
111 
 
Scarantino C W, Rini C J, Aquino M, Carrea T B, Ornitz R D, Anscher M S and Black R D 
2005 Initial clinical results of an in vivo dosimeter during external beam radiation therapy 
Int. J. Radiat. Oncol. Biol. Phys. 62 606–13 
 
Schaffner B and Pedroni E 1998 The precision of proton range calculations in proton 
radiotherapy treatment planning: experimental verification of the relation between CT-HU 
and proton stopping power Phys. Med. Biol. 43 1579–92 
 
Schneider U, Besserer J, Pemler P, Dellert M, Moosburger M, Pedroni E and Kaser-Hotz B 
 2004 First proton radiography of an animal patient Med. Phys. 31 1046–51 
 
Schneider U and Pedroni E 1995 Proton radiography as a tool for quality control Med. Phys. 
22 353–63 
 
Schneider U, Pedroni E and Lomax A 1996 The calibration of CT Hounsfield units for 
radiotherapy treatment planning Phys. Med. Biol. 41 111–24 
 
Schneider W, Bortfeld T, and Schlegel W 2000 Correlation between CT numbers and tissue 
parameters needed for Monte Carlo simulations of clinical dose distributions Phys. Med. 
Biol. 45 459–78 
 
  
112 
 
Schulte R W, Shahnazi K and Bashkirov V 2002 Proton computed tomography for clinical 
applications—a research proposal to Loma Linda University Medical School Research 
Support Committee (available at 
http://scipp.ucsc.edu/∼hartmut/Radiobiology/pCT/Proton%20CT%20LLU%20App_1_9.pdf) 
 
Seravalli E , Robert C, Bauer J, Stichelbaut F, Kurz C, Smeets J, Van Ngoc TC, Schaart DR, 
Buvat I, Parodi K and Verhaegen F 2012 Monte Carlo calculations of positron emitter yields 
in proton radiotherapy Phys. Med. Biol. 57 1659–73 
 
Shakirin G, Braess H, Fiedler F, Kunath D, Laube K, Parodi K, Priegnitz M and Enghardt W 
2011 Implementation and workflow for PET monitoring of therapeutic ion irradiation: a 
comparison of in-beam, in-room, and off-line techniques Phys. Med. Biol. 56 1281–98 
 
Sjŏstrŏm E 1981 Wood Chemistry – Fundamentals and Applications Academic Press, San 
Diego, California 92101–4495, USA 
 
Stevens S K, Moore S G and Kaplan I D 1990 Early and late bone-marrow changes after 
irradiation: MR evaluation Am. J. Roentgenol. 154 745–50 
 
Steward V W and Koehler A M 1973a Proton radiographic detection of strokes Nature 7 
38–40 
 
  
113 
 
Steward V W and Koehler A M 1973b Proton beam radiography in tumor detection Science 
2 179 913–4 
 
Tindel N L, Marcillo A E, Tay B K, Bunge R P and Eismont F J 2001 The effect of 
surgically implanted bullet fragments on the spinal cord in a rabbit model J. Bone Joint 
Surg. Am. 83-A 884–90 
 
Titt U, Sahoo N, Ding X, Zheng Y, Newhauser WD, Zhu XR, Polf JC, Gillin MT and 
Mohan R 2008 Assessment of the accuracy of an MCNPX-based Monte Carlo simulation 
model for predicting three-dimensional absorbed dose distributions. Phys. Med. Biol. 53 
4455–70 
 
Tomitani T, Pawelke J, Kanazawa M, Yoshikawa K, Yoshida K, Sato M, Takami A, Koga 
M, Futami Y, Kitagawa A, Urakabe E, Suda M, Mizuno H, Kanai T, Matsuura H, Shinoda I 
and Takizawa S 2003 Washout studies of 11C in rabbit thigh muscle implanted by 
secondary beams of HIMAC Phys. Med. Biol. 48 875–89 
 
Tuckwell W and Bezak E 2007 Calculation of the positron distribution from 15O nuclei 
formed in nuclear reactions in human tissue during proton therapy Phys. Med. Biol. 52 
2483–98 
 
  
114 
 
Unkelbach J, Bortfeld T, Martin B C and Soukup M 2009 Reducing the sensitivity of IMPT 
treatment plans to setup errors and range uncertainties via probabilistic treatment planning 
Med. Phys. 36 149–63 
 
Urakabe E, Kanai T, Kanazawa M, Kitagawa A, Noda K, Tomitani T, Suda M, Iseki Y, 
Hanawa K, Sato K, Shimbo M, Mizuno H, Hirata Y, Futami Y, Iwashita Y and Noda A 
2001 Spot scanning using radioactive C-11 beams for heavy-ion radiotherapy Jpn J Appl 
Phys 1 40 2540–8 
 
Waters L S, Hendricks J and McKinney G 2005 MCNPX version 2.5.0. Los Alamos: Los 
Alamos National Laboratory 
 
Wilson R R 1946 Radiological use of fast protons Radiology 47 487–91 
 
Woodard H Q and White D R 1986 The composition of body tissues Br. J. Radiol. 59 1209–
19 
 
Yang M, Virshup G, Clayton J, Zhu X R, Mohan R and Dong L 2010 Theoretical variance 
analysis of single- and dual-energy computed tomography methods for calculating proton 
stopping power ratios of biological tissues Phys. Med. Biol. 55 1343–62 
 
  
115 
 
Yankelevitz D F, Henschke C I, Knapp P H, Nisce L, Yi Y and Cahill P 1991 Effect of 
radiation therapy on thoracic and lumbar bone marrow: evaluation with MR imaging AJR 
157 87–92 
 
Zhu X, España S, Daartz J, Liebsch N, Ouyang J, Paganetti H, Bortfeld T and El Fakhri G 
2011 Monitoring proton radiation therapy with in-room PET imaging Phys. Med. Biol. 56 
4041–57 
 
Zygmanski P, Gall K P, Rabin M S Z and Rosenthal S J 2000 The measurement of proton 
stopping power using proton-cone-beam computed tomography Phys. Med. Biol. 45 511–28 
  
116 
 
VITA 
 
Jongmin Cho was born in Anyang, South Korea in May 24, 1973, as the youngest child of 
Youngbae Cho and Soonin Cha. After earning bachelor’s degree in electrical engineering 
from Inha University and master’s degree in high energy physics from Seoul National 
University, he went on to study medical physics at The University of British Columbia and 
BC Cancer Agency. Upon receiving master’s degree in medical physics, he went on to work 
at Roger Maris Cancer Center followed by Loma Linda University Medical Center as a 
medical physics resident, then medical physicist and a clinical faculty. During his 
employment, he obtained his board certification with American Board of Radiology. In the 
fall of 2010, he started his PhD education with The University of Texas Health Science 
Center at Houston Graduate School of Biomedical Sciences and M. D. Anderson Cancer 
Center. 
 
Permanent e-mail address: 
Jongmin.Cho@gmail.com 
